Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors

ABSTRACT

The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis and catalysis.

This is a Divisional of application Ser. No. 08/332,046, filed Nov. 1,1994; which is a Continuation of Ser. No. 07/796,805, filed Nov. 25,1991, which is a Divisional of Ser. No. 07/580,374, filed Sep. 11, 1990,abandoned.

The present invention relates to single domain ligands derived frommolecules in the immunoglobulin (Ig) superfamily, receptors comprisingat least one such ligand, methods for cloning, amplifying and expressingDNA sequences encoding such ligands, methods for the use of said DNAsequences in the production of Ig-type molecules and said ligands orreceptors, and the use of said ligands or receptors in therapy,diagnosis or catalysis.

A list of references is appended to the end of the description. Thedocuments listed therein are referred to in the description by number,which is given in square brackets [].

The Ig superfamily includes not only the Igs themselves but also suchmolecules as receptors on lymphoid cells such as T lymphocytes.Immunoglobulins comprise at least one heavy and one light chaincovalently bonded together. Each chain is divided into a number ofdomains. At the N terminal end of each chain is a variable domain. Thevariable domains on the heavy and light chains fit together to form abinding site designed to receive a particular target molecule. In thecase of Igs, the target molecules are antigens. T-cell receptors havetwo chains of equal size, the α and β chains, each consisting of twodomains. At the N-terminal end of each chain is a variable domain andthe variable domains on the α and β chains are believed to fit togetherto form a binding site for target molecules, in this case peptidespresented by a histocompatibility antigen. The variable domains are socalled because their amino acid sequences vary particularly from onemolecule to another. This variation in sequence enables the molecules torecognise an extremely wide variety of target molecules.

Much research has been carried out on Ig molecules to determine how thevariable domains are produced. It has been shown that each variabledomain comprises a number of areas of relatively conserved sequence andthree areas of hypervariable sequence. The three hypervariable areas aregenerally known as complementarity determining regions (CDRs).

Crystallographic studies have shown that in each variable domain of anIg molecule the CDRs are supported on framework areas formed by theareas of conserved sequences. The three CDRs are brought together by theframework areas and, together with the CDRs on the other chain, form apocket in which the target molecule is received.

Since the advent of recombinant DNA technology, there has been muchinterest in the use of such technology to clone and express Ig moleculesand derivatives thereof. This interest is reflected in the numbers ofpatent applications and other publications on the subject.

The earliest work on the cloning and expression of full Igs in thepatent literature is EP-A-0 120 694 (Boss). The Boss application alsorelates to the cloning and expression of chimeric antibodies. Chimericantibodies are Ig-type molecules in which the variable domains from oneIg are fused to constant domains from another Ig. Usually, the variabledomains are derived from an Ig from one species (often a mouse Ig) andthe constant domains are derived from an Ig from a different species(often a human Ig)

A later European patent application, EP-A-0 125 023 (Genentech), relatesto much the same subject as the Boss application, but also relates tothe production by recombinant DNA technology of other variations ofIg-type molecules.

EP-A-0 194 276 (Neuberger) discloses not only chimeric antibodies of thetype disclosed in the Boss application but also chimeric antibodies inwhich some or all of the constant domains have been replaced by non-Igderived protein sequences. For instance, the heavy chain CH2 and CH3domains may be replaced by protein sequences derived from an enzyme or aprotein toxin.

EP-A-0 239 400 (Winter) discloses a different approach to the productionof Ig molecules. In this approach, only the CDRs from a first type of Igare grafted onto a second type of Ig in place of its normal CDRs. The Igmolecule thus produced is predominantly of the second type, since theCDRs form a relatively small part of the whole Ig. However, since theCDRs are the parts which define the specificity of the Ig, the Igmolecule thus produced has its specificity derived from the first Ig.

Hereinafter, chimeric antibodies, CDR-grafted Igs, the alteredantibodies described by Genentech, and fragments, of such Igs such asF(ab′)₂ and Fv fragments are referred to herein as modified antibodies.

One of the main reasons for all the activity in the Ig field usingrecombinant DNA technology is the desire to use Igs in therapy. It iswell known that, using the hybridoma technique developed by Kohler andMilstein, it is possible to produce monoclonal antibodies (MAbs) ofalmost any specificity. Thus, MAbs directed against cancer antigens havebeen produced. It is envisaged that these MAbs could be covalentlyattached or fused to toxins to provide “magic bullets” for use in cancertherapy. MAbs directed against normal tissue or cell surface antigenshave also been produced. Labels can be attached to these so that theycan be used for in vivo imaging.

The major obstacle to the use of such MAbs in therapy or in vivodiagnosis is that the vast majority of MAbs which are produced are ofrodent, in particular mouse, origin. It is very difficult to producehuman MAbs. Since most MAbs are derived from non-human species, they areantigenic in humans. Thus, administration of these MAbs to humansgenerally results in an anti-Ig response being mounted by the human.Such a response can interfere with therapy or diagnosis, for instance bydestroying or clearing the antibody quickly, or can cause allergicreactions or immune complex hypersensitivity which has adverse effectson the patient.

The production of modified Igs has been proposed to ensure that the Igadministered to a patient is as “human” as possible, but still retainsthe appropriate specificity. It is therefore expected that modified Igswill be as effective as the MAb from which the specificity is derivedbut at the same time not very antigenic. Thus, it should be possible touse the modified Ig a reasonable number of times in a treatment ordiagnosis regime.

At the level of the gene, it is known that heavy chain variable domainsare encoded by a “rearranged” gene which is built from three genesegments: an “unrearranged” VH gene (encoding the N-terminal threeframework regions, first two complete CDRs and the first part of thethird CDR), a diversity (DH)-segment (DH) (encoding the central portionof the third CDR) and a joining segment (JH) (encoding the last part ofthe third CDR and the fourth framework region). In the maturation ofB-cells, the genes rearrange so that each unrearranged VH gene is linkedto one DH gene and one JH gene. The rearranged gene corresponds toVH-DH-JH. This rearranged gene is linked to a gene which encodes theconstant portion of the Ig chain.

For light chains, the situation is similar, except that for light chainsthere is no diversity region. Thus light chain variable domains areencoded by an “unrearranged” VL gene and a JL gene. There are two typesof light chains, kappa (κ) or lambda (λ), which are built respectivelyfrom unrearranged Vκ genes and Jκ segments, and from unrearranged Vλgenes and Jλ segments.

Previous work has shown that it is necessary to have two variabledomains in association together for efficient binding. For example, theassociated heavy and light chain variable domains were shown to containthe antigen binding site [1]. This assumption is borne out by X-raycrystallographic studies of crystallised antibody/antigen complexes[2-6] which show that both the heavy and light chains of the antibody'svariable domains contact the antigen. The expectation that associationof heavy and light chain variable domains is necessary for efficientantigen binding underlies work to co-secrete these domains from bacteria[1], and to link the domains together by a short section of polypeptideas in the single chain antibodies [8, 9].

Binding of isolated heavy and light chains had also been detected.However the evidence suggested strongly that this was a property ofheavy or light chain dimers. Early work, mainly with polyclonalantibodies, in which antibody heavy and light chains had been separatedunder denaturing conditions [10] suggested that isolated antibody heavychains could bind to protein antigens [11] or hapten [12]. The bindingof protein antigen was not characterised, but the hapten-bindingaffinity of the heavy chain fragments was reduced by two orders ofmagnitude [12] and the number of hapten molecules binding were variouslyestimated as 0.14 or 0.37 [13] or 0.26 [14] per isolated heavy chain.Furthermore binding of haptens was shown to be a property of dimericheavy or dimeric light chains [14]. Indeed light chain dimers have beencrystallised. It has been shown that in light chain diners the twochains form a cavity which is able to bind to a single molecule ofhapten [15].

This confirms the assumption that, in order to obtain efficient binding,it is necessary to have a diner, and preferably a heavy chain/lightchain dimer, containing the respective variable domains. This assumptionalso underlies the teaching of the patent references cited above,wherein the intention is always to produce dimeric, and preferablyheavy/light chain dimeric, molecules.

It has now been discovered, contrary to expectations, that isolated Igheavy chain variable domains can bind to antigen in a 1:1 ratio and withbinding constants of equivalent magnitude to those of complete antibodymolecules. In view of what was known up until now and in view of theassumptions made by those skilled in the art, this is highly surprising.

Therefore, according to a first aspect of the present invention, thereis provided a single domain ligand consisting at least part of thevariable domain of one chain of a molecule from the Ig superfamily.

Preferably, the ligand consists of the variable domain of an Ig light,or, most preferably, heavy chain.

The ligand may be produced by any known technique, for instance bycontrolled cleavage of Ig superfamily molecules or by peptide synthesis.However, preferably the ligand is produced by recombinant DNAtechnology. For instance, the gone encoding the rearranged gene for aheavy chain variable domain may be produced, for instance by cloning orgene synthesis, and placed into a suitable expression vector. Theexpression vector is then used to transform a compatible host cell whichis then cultured to allow the ligand to be expressed and, preferably,secreted.

If desired, the gene for the ligand can be mutated to improve theproperties of the expressed domain, for example to increase the yieldsof expression or the solubility of the ligand, to enable the ligand tobind better, or to introduce a second site for covalent attachment (byintroducing chemically reactive residues such as cysteine and histidine)or non-covalent binding of other molecules. In particular it would bedesirable to introduce a second site for binding to serum components, toprolong the residence time of the domains in the serum; or for bindingto molecules with effecter functions, such as components of complement,or receptors on the surfaces of cells.

Thus, hydrophobic residues which would normally be at the interface ofthe heavy chain variable domain with the light chain variable domaincould be mutated to more hydrophilic residues to improve solubility;residues in the CDR loops could be mutated to improve antigen binding;residues on the other loops or parts of β-sheet could be mutated tointroduce new binding activities. Mutations could include single pointmutations, multiple point mutations or more extensive changes and couldbe introduced by any of a variety of recombinant DNA methods, forexample gene synthesis, site directed mutagenesis or the polymerasechain reaction.

Since the ligands of the present invention have equivalent bindingaffinity to that of complete Ig molecules, the ligands can be used inmany of the ways as are Ig molecules or fragments. For example, Igmolecules have been used in therapy (such as in treating cancer,bacterial and viral diseases), in diagnosis (such as pregnancy testing),in vaccination (such as in producing anti-idiotypic antibodies whichmimic antigens), in modulation of activities of hormones or growthfactors, in detection, in biosensors and in catalysis.

It is envisaged that the small size of the ligands of the presentinvention may confer some advantages over complete antibodies, forexample, in neutralising the activity of low molecular weight drugs(such as digoxin) and allowing their filtration from the kidneys withdrug attached; in penetrating tissues and tumours; in neutralisingviruses by binding to small conserved regions on the surfaces of virusessuch as the “canyon” sites of viruses [16]; in high resolution epitopemapping of proteins; and in vaccination by ligands which mimic antigens.

The present invention also provides receptors comprising a ligandaccording to the first aspect of the invention linked to one or more ofan effector molecule, a label, a surface, or one or more other ligandshaving the same or different specificity.

A receptor comprising a ligand linked to an effector molecule may be ofuse in therapy. The effector molecule may be a toxin, such as ricin orpseudomonas exotoxin, an enzyme which is able to activate a prodrug, abinding partner or a radio-isotope. The radio-isotope may be directlylinked to the ligand or may be attached thereto by a chelating structurewhich is directly linked to the ligand. Such ligands with attachedisotopes are much smaller than those based on Fv fragments, and couldpenetrate tissues and access tumours more readily.

A receptor comprising a ligand linked to a label may be of use indiagnosis. The label may be a heavy metal atom or a radio-isotope, inwhich case the receptor can be used for in vivo imaging using X-ray orother scanning apparatus. The metal atom or radio-isotope may beattached to the ligand either directly or via a chelating structuredirectly linked to the ligand. For in vitro diagnostic testing, thelabel may be a heavy metal atom, a radio-isotope, an enzyme, afluorescent or coloured molecule or a protein or peptide tag which canbe detected by an antibody, an antibody fragment or another protein.Such receptors would be used in any of the known diagnostic tests, suchas ELISA or fluorescence-linked assays.

A receptor comprising a ligand linked to a surface, such as achromatography medium, could be used for purification of other moleculesby affinity chromatography. Linking of ligands to cells, for example tothe outer membrane proteins of E. coli or to hydrophobic tails whichlocalise the ligands in the cell membranes, could allow a simplediagnostic test in which the bacteria or cells would agglutinate in thepresence of molecules bearing multiple sites for binding the ligand(s).

Receptors comprising at least two ligands can be used, for instance, indiagnostic tests. The first ligand will bind to a test antigen and thesecond ligand will bind to a reporter molecule, such as an enzyme, afluorescent dye, a coloured dye, a radio-isotope or a coloured-,fluorescently- or radio-labelled protein.

Alternatively, such receptors may be useful in increasing the binding toan antigen. The first ligand will bind to a first epitope of the antigenand the second ligand will bind to a second epitope. Such receptors mayalso be used for increasing the affinity and specificity of binding todifferent antigens in close proximity on the surface of cells. The firstligand will bind to the first antigen and the second epitope to thesecond antigen: strong binding will depend on the co-expression of theepitopes on the surface of the call. This may be useful in therapy oftumours, which can have elevated expression of several surface markers.Further ligands could be added to further improve binding orspecificity. Moreover, the use of strings of ligands, with the same ormultiple specificities, creates a larger molecule which is less readilyfiltered from the circulation by the kidney.

For vaccination with ligands which mimic antigens, the use of strings ofligands may prove more effective than single ligands, due to repetitionof the immunising epitopes.

If desired, such receptors with multiple ligands could include effectormolecules or labels so that they can be used in therapy or diagnoses asdescribed above.

The ligand may be linked to the other part of the receptor by anysuitable means, for instance by covalent or non-covalent chemicallinkages. However, where the receptor comprises a ligand and anotherprotein molecule, it is preferred that they are produced by recombinantDNA technology as a fusion product. If necessary, a linker peptidesequence can be placed between the ligand and the other protein moleculeto provide flexibility.

The basic techniques for manipulating Ig molecules by recombinant DNAtechnology are described in the patent references cited above. These maybe adapted in order to allow for the production of ligands and receptorsaccording to the invention by means of recombinant DNA technology.

Preferably, where the ligand is to be used for in vivo diagnosis ortherapy in humans, it is humanised, for instance by CDR replacement asdescribed in EP-A-0 239 400.

In order to obtain a DNA sequence encoding a ligand, it is generallynecessary firstly to produce a hybridoma which secretes an appropriateMAb. This can be a very time consuming method. Once an immunised animalhas been produced, it is necessary to fuse separated spleen cells with asuitable myeloma cell line, grow up the cell lines thus produced, selectappropriate lines, reclone the selected lines and reselect. This cantake some long time. This problem also applies to the production ofmodified Igs.

A further problem with the production of ligands, and also receptorsaccording to the invention and modified Igs, by recombinant DNAtechnology is the cloning of the variable domain encoding sequences fromthe hybridoma which produces the MAb from which the specificity is to bederived. This can be a relatively long method involving the productionof a suitable probe, construction of a clone library from cDNA orgenomic DNA, extensive probing of the clone library, and manipulation ofany isolated clones to enable the cloning into a suitable expressionvector. Due to the inherent variability of the DNA sequences encoding Igvariable domains, it has not previously been possible to avoid such timeconsuming work. It is therefore a further aim of the present inventionto provide a method which enables substantially any sequence encoding anIg superfamily molecule variable domain (ligand) to be cloned in areasonable period of time.

According to another aspect of the present invention therefore, there isprovided a method of cloning a sequence (the target sequence) whichencodes at least part of the variable domain of an Ig superfamilymolecule, which method comprises:

(a) providing a sample of double stranded (ds) nucleic acid whichcontains the target sequence;

(b) denaturing the sample so as to separate the two strands;

(c) annealing to the sample a forward and a back oligonucleotide primer,the forward primer being specific for a sequence at or adjacent the 3′end of the sense strand of the target sequence, the back primer beingspecific for a sequence at or adjacent the 3′ end of the antisensestrand of the target sequence, under conditions which allow the primersto hybridise to the nucleic acid at or adjacent the target sequence;

(d) treating the annealed sample with a DNA polymerase enzyme in thepresence of deoxynucleoside triphosphates under conditions which causeprimer extension to take place; and

(e) denaturing the sample under conditions such that the extendedprimers become separated from the target sequence.

Preferably, the method of the present invention further includes thestep (f) of repeating steps (c) to (e) on the denatured mixture aplurality of times.

Preferably, the method of the present invention is used to clonecomplete variable domains from Ig molecules, most preferably from Igheavy chains. In the most preferred instance, the method will produce aDNA sequence encoding a ligand according to the present invention.

In step (c) recited above, the forward primer becomes annealed to thesense strand of the target sequence at or adjacent the 3′ end of thestrand. In a similar manner, the back primer becomes annealed to theantisense strand of the target sequence at or adjacent the 3′ end of thestrand. Thus, the forward primer anneals at or adjacent the region ofthe ds nucleic acid which encodes the C terminal end of the variableregion or domain. Similarly, the back primer anneals at or adjacent theregion of the ds nucleic acid which encodes the N-terminal end of thevariable domain.

In step (d), nucleotides are added onto the 3′ end of the forward andback primers in accordance with the sequence of the strand to which theyare annealed. Primer extension will continue in this manner untilstopped by the beginning of the denaturing step (e). It must thereforebe ensured that step (d) is carried out for a long enough time to ensurethat the primers are extended so that the extended strands totallyoverlap one another.

In step (e), the extended primers are separated from the ds nucleicacid. The ds nucleic acid can then serve again as a substrate to whichfurther primers can anneal. Moreover, the extended primers themselveshave the necessary complementary sequences to enable the primers toanneal thereto.

During further cycles, if step (f) is used, the amount of extendedprimers will increase exponentially so that at the and of the cyclesthere will be a large quantity of cDNA having sequences complementary tothe sense and antisense strands of the target sequence. Thus, the methodof the present invention will result in the accumulation of a largequantity of cDNA which can form ds cDNA encoding at least part of thevariable domain.

As will be apparent to the skilled person, some of the steps in themethod may be carried out simultaneously or sequentially as desired.

The forward and back primers may be provided as isolatedoligonucleotides, in which case only two oligonucleotides will be used.However, alternatively the forward and back primers may each be suppliedas a mixture of closely related oligonucleotides. For instance, it maybe found that at a particular point in the sequence to which the primeris to anneal, there is the possibility of nucleotide variation. In thiscase a primer may be used for each possible nucleotide variation.Furthermore it may be possible to use two or more sets of “nested”primers in the method to enhance the specific cloning of variable regiongenes.

The method described above is similar to the method described by Saikiet al. [17]. A similar method is also used in the methods described inEP-A-0 200 362. In both cases the method described is carried out usingprimers which are known to anneal efficiently to the specifiednucleotide sequence. In neither of these disclosures was it suggestedthat the method could be used to clone Ig parts of variable domainencoding sequences, where the target sequence contains inherently highlyvariable areas.

The ds nucleic acid sequence used in the method of the present inventionmay be derived mRNA. For instance, RNA may be isolated in known mannerfrom a cell or cell line which is known to produce Igs. mRNA may beseparated from other RNA by oligo-dT chromatography. A complementarystrand of cDNA may then be synthesised on the mRNA template, usingreverse transcriptase and a suitable primer, to yield an RNA/DNAheteroduplex. A second strand of DNA can be made in one of several ways,for example, by priming with RNA fragments of the mRNA strand (made byincubating RNA/DNA heteroduplex with RNase H) and using DNA polymerase,or by priming with a synthetic oligodeoxynucleotide primer which annealsto the 3′ end of the first strand and using DNA polymerase. It has beenfound that the method of the present invention can be carried cut usingds cDNA prepared in this way.

When making such ds cDNA, it is possible to use a forward primer whichanneals to a sequence in the CH1 domain (for a heavy chain variabledomain) or the Cλ or Cκ domain (for a light chain variable domain).These will be located in close enough proximity to the target sequenceto allow the sequence to be cloned.

The back primer may be one which anneals to a sequence at the N-terminalend of the VH1, Vκ or Vλ domain. The back primer may consist of aplurality of primers having a variety of sequences designed to becomplementary to the various families of VH1, Vκ or Vλ sequences known.Alternatively the back primer may be a single primer having a consensussequence derived from all the families of variable region genes.

Surprisingly, it has been found that the method of the present inventioncan be carried out using genomic DNA. If genomic DNA is used, there is avery large amount of DNA present, including actual coding sequences,introns and untranslated sequences between genes. Thus, there isconsiderable scope for non-specific annealing under the conditions used.However, it has surprisingly been found that there is very littlenon-specific annealing. It is therefore unexpected that it has provedpossible to clone the genes of Ig-variable domains from genomic DNA.

Under some circumstances the use of genomic DNA may prove advantageouscompared with use of mRNA, as the mRNA is readily degraded, andespecially difficult to prepare from clinical samples of human tissue.

Thus, in accordance with an aspect of the present invention, the dsnucleic acid used in step (a) is genomic DNA.

When using genomic DNA as the ds nucleic acid source, it will not bepossible to use as the forward primer an oligonucleotide having asequence complementary to a sequence in a constant domain. This isbecause, in genomic DNA, the constant domain genes are generallyseparated from the variable domain genes by a considerable number ofbase pairs. Thus, the site of annealing would be too remote from thesequence to be cloned.

It should be noted that the method of the present invention can be usedto clone both rearranged and unrearranged variable domain sequences fromgenomic DNA. It is known that in germ line genomic DNA the three genes,encoding the VH, DH and JH respectively, are separated from one anotherby considerable numbers of base pairs. On maturation of the immuneresponse, these genes are rearranged so that the VH, DH and JH genes arefused together to provide the gene encoding the whole variable domain(see FIG. 1). By using a forward primer specific for a sequence at oradjacent the 3′ end of the sense strand of the genomic “unrearranged” VHgene, it is possible to clone the “unrearranged” VH gene alone, withoutalso cloning the DH and JH genes. This can be of use in that it willthen be possible to fuse the VH gene onto pre-cloned or synthetic DH andDH genes. In this way, rearrangement of the variable domain genes can becarried out in vitro.

The oligonucleotide primers used in step (c) may be specificallydesigned for use with a particular target sequence. In this case, itwill be necessary to sequence at least the 5′ and 3′ ends of the targetsequence so that the appropriate oligonucleotides can be synthesised.However, the present inventors have discovered that it is not necessaryto use such specifically designed primers. Instead, it is possible touse a species specific general primer or a mixture of such primers forannealing to each end of the target sequence. This is not particularlysurprising as regards the 3′ end of the target sequence. It is knownthat this end of the variable domain encoding sequence leads into asegment encoding JH which is known to be relatively conserved. However,it was surprisingly discovered that, within a single species, thesequence at the 5′ end of the target sequence is sufficiently wellconserved to enable a species specific general primer or a mixturethereof to be designed for the 5′ end of the target sequence.

Therefore according to a preferred aspect of the present invention, instep (c) the two primers which are used are species specific generalprimers, whether used as single primers or as mixtures of primers. Thisgreatly facilitates the cloning of any undetermined target sequencesince it will avoid the need to carry out any sequencing on the targetsequence in order to produce target sequence-specific primers. Thus themethod of this aspect of the invention provides a general method forcloning variable region or domain encoding sequences of a particularspecies.

Once the variable domain gene has been cloned using the method describedabove, it may be directly inserted into an expression vector, forinstance using the PCR reaction to paste the gene into a vector.

Advantageously, however, each primer includes a sequence including arestriction enzyme recognition site. The sequence recognised by therestriction enzyme need not be in the part of the primer which annealsto the ds nucleic acid, but may be provided as an extension which doesnot anneal. The use of primers with restriction sites has the advantagethat the DNA can be cut with at least one restriction enzyme whichleaves 3′ or 5′ overhanging nucleotides. Such DNA is more readily clonedinto the corresponding sites on the vectors than blunt end fragmentstaken directly from the method. The ds cDNA produced at the end of thecycles will thus be readily insertable into a cloning vector by use ofthe appropriate restriction enzymes. Preferably the choice ofrestriction sites is such that the ds cDNA is cloned directly into anexpression vector, such that the ligand encoded by the gene isexpressed. In this case the restriction site is preferably located inthe sequence which is annealed to the ds nucleic acid.

Since the primers may not have a sequence exactly complementary to thetarget sequence to which it is to be annealed, for instance because ofnucleotide variations or because of the introduction of a restrictionenzyme recognition site, it may be necessary to adjust the conditions inthe annealing mixture to enable the primers to anneal to the ds nucleicacid. This is well within the competence of the person skilled in theart and needs no further explanation.

In step (d), any DNA polymerase may be used. Such polymerases are knownin the art and are available commercially. The conditions to be usedwith each polymerase are well known and require no further explanationhere. The polymerase reaction will need to be carried out in thepresence of the four nucleoside triphosphates. These and the polymeraseenzyme may already be present in the sample or may be provided afreshfor each cycle.

The denaturing step (e) may be carried out, for instance, by heating thesample, by use of chaotropic agents, such as urea or guanidine, or bythe use of charges in ionic strength or pH. Preferably, denaturing iscarried out by heating since this is readily reversible. Where heatingis used to carry out the denaturing, it will be usual to use athermostable DNA polymerase, such as Taq polymerase, since this will notneed replenishing at each cycle.

If heating is used to control the method, a suitable cycle of heatingcomprises denaturation at about 95° C. for about 1 minute, annealing atfrom 30° C. to 65° C. for about 1 minute and primer extension at about75° C. for about 2 minutes. To ensure that elongation and renaturationis complete, the mixture after the final cycle is preferably held atabout 60° C. for about 5 minutes.

The product ds cDNA may be separated from the mixture for instance bygel electrophoresis using agarose gels. However, if desired, the ds cDNAmay be used in unpurified form and inserted directly into a suitablecloning or expression vector by conventional methods. This will beparticularly easy to accomplish if the primers include restrictionenzyme recognition sequences.

The method of the present invention may be used to make variations inthe sequences encoding the variable domains. For example this may beacheived by using a mixture of related oligonucleotide primers as atleast one of the primers. Preferably the primers are particularlyvariable in the middle of the primer and relatively conserved at the 5′and 3′ ends. Preferably the ends of the primers are complementary to theframework regions of the variable domain, and the variable region in themiddle of the primer covers all or part of a CDR. Preferably a forwardprimer is used in the area which forms the third CDR. If the method iscarried out using such a mixture of oligonucleotides, the product willbe a mixture of variable domain encoding sequences. Moreover, variationsin the sequence may be introduced by incorporating some mutagenicnucleotide triphosphates in step (d), such that point mutations arescattered throughout the target region. Alternatively such pointmutations are introduced by performing a large number of cycles ofamplification, as errors due to the natural error rate of the DNApolymerase are amplified, particularly when using high concentrations ofnucleoside triphosphates.

The method of this aspect of the present invention has the advantagethat it greatly facilitates the cloning of variable domain encodingsequences directly from mRNA or genomic DNA. This in turn willfacilitate the production of modified Ig-type molecules by any of theprior art methodes referred to above. Further, target genes can becloned from tissue samples containing antibody producing cells, and thegenes can be sequenced. By doing this, it will be possible to lookdirectly at the immune repertoire of a patient. This “fingerprinting” ofa patient's immune repertoire could be of use in diagnosis, for instanceof auto-immune diseases.

In the method for amplifying the amount of a gene encoding a variabledomain, a single set of primers is used in several cycles of copying viathe polymerase chain reaction. As a less preferred alternative, there isprovided a second method which comprises steps (a) to (d) as above,which further includes the steps of:

(g) treating the sample of ds cDNA with traces of DNAse in the presenceof DNA polymerase I to allow nick translation of the DNA; and

(h) cloning the ds cDNA into a vector.

If desired, the second method may further include the steps of:

(i) digesting the DNA of recombinant plasmids to release DNA fragmentscontaining genes encoding variable domains; and

(j) treating the fragments in a further set of steps (c) to (h).

Preferably the fragments are separated from the vector and from otherfragments of the incorrect size by gel electrophoresis.

The steps (a) to (d) then (g) to (h) can be followed once, butpreferably the entire cycle (c) to (d) and (g) to (j) is repeated atleast once. In this way a priming step, in which the genes arespecifically copied, is followed by a cloning step, in which the amountof genes is increased.

In step (a) the ds cDNA is derives from mRNA. For Ig derived variabledomains, the mRNA is preferably be isolated from lymphocytes which havebeen stimulated to enhance production of mRNA.

In each step (c) the set of primers are preferably different from theprevious step (c), so as to enhance the specificity of copying. Thus thesets of primers form a nested set. For example, for cloning of Ig heavychain variable domains, the first set of primers may be located withinthe signal sequence and constant region, as described by Larrick et al.,[18], and the second set of primers entirely within the variable region,as described by Orlandi et al., [19]. Preferably the primers of step (c)include restriction sites to facilitate subsequent cloning. In the lastcycle the set of primers used in step (c) should preferably includerestriction sites for introduction into expression vectors. In step (g)possible mismatches between the primers and the template strands arecorrected by “nick translation”. In step (h), the ds cDNA is preferablycleaved with restriction enzymes at sites introduced into the primers tofacilitate the cloning.

According to another aspect of the present invention the product ds cDNAis cloned directly into an expression vector. The host may beprokaryotic or eukaryotic, but is preferably bacterial. Preferably thechoice of restriction sites in the primers and in the vector, and otherfeatures of the vector will allow the expression of complete ligands,while preserving all those features of the amino acid sequence which aretypical of the (methoded) ligands. For example, for expression of therearranged variable genes, the primers would be chosen to allow thecloning of target sequences including at least all the three CDRsequences. The cloning vector would then encode a signal sequence (forsecretion of the ligand), and sequences encoding the N-terminal end ofthe first framework region, restriction sites for cloning and then theC-terminal end of the last (fourth) framework region.

For expression of unrearranged VH genes as part of complete ligands, theprimers would be chosen to allow the cloning of target sequencesincluding at least the first two CDRs. The cloning vector could thenencode signal sequence, the N-terminal end of the first frameworkregion, restriction sites for cloning and then the C-terminal end of thethird framework region, the third CDR and fourth framework region.

Primers and cloning vectors may likewise be devised for expression ofsingle CDRs, particularly the third CDR, as parts of complete ligands.The advantage of cloning repertoires of single CDRs would permit thedesign of a “universal” set of framework regions, incorporatingdesirable properties such as solubility.

Single ligands could be expressed alone or in combination with acomplementary variable domain. For example, a heavy chain variabledomain can be expressed either as an individual domain or, if it isexpressed with a complementary light chain variable domain, as anantigen binding site. Preferably the two partners would be expressed inthe same cell, or secreted from the same cell, and the proteins allowedto associate non-covalently to form an Fv fragment. Thus the two genesencoding the complementary partners can be placed in tandem andexpressed from a single vector, the vector including two sets ofrestriction sites.

Preferably the genes are introduced sequentially: for example the heavychain variable domain can be cloned first and then the light chainvariable domain. Alternatively the two genes are introduced into thevector in a single step, for example by using the polymerase chainreaction to paste together each gene with any necessary interveningsequence, as essentially described by Yon and Fried [29]. The twopartners could be also expressed as a linked protein to produce a singlechain Fv fragment, using similar vectors to those described above. As afurther alternative the two genes may be placed in two differentvectors, for example in which one vector is a phage vector and the otheris a plasmid vector.

Moreover, the cloned ds cDNA may be inserted into an expression vectoralready containing sequences encoding one or more constant domains toallow the vector to express Ig-type chains. The expression of Fabfragments, for example, would have the advantage over Fv fragments thatthe heavy and light chains would tend to associate through the constantdomains in addition to the variable domains. The final expressionproduct may be any of the modified Ig-type molecules referred to above.

The cloned sequence may also be inserted into an expression vector sothat it can be expressed as a fusion protein. The variable domainencoding sequence may be linked directly or via a linker sequence to aDNA sequence encoding any protein effector molecule, such as a toxin,enzyme, label or another ligand. The variable domain sequences may alsobe linked to proteins on the outer side of bacteria or phage. Thus, themethod of this aspect of the invention may be used to produce receptorsaccording to the invention.

According to another aspect of the invention, the cloning of ds cDNAdirectly for expression permits the rapid construction of expressionlibraries which can be screened for binding activities. For Ig heavy andlight chain variable genes, the ds cDNA may comprise variable genesisolated as complete rearranged genes from the animal, or variable genesbuilt from several different sources, for example a repertoire ofunrearranged VH genes combined with a synthetic repertoire of DH and JHgenes. Preferably repertoires of genes encoding Ig heavy chain variabledomains are prepared from lymphocytes of animals immunised with anantigen.

The screening method may take a range of formats well known in the art.For example Ig heavy chain variable domains secreted from bacteria maybe screened by binding to antigen on a solid phase, and detecting thecaptured domains by antibodies. Thus the domains may be screened bygrowing the bacteria in liquid culture and binding to antigen coated onthe surface of ELISA plates. However, preferably bacterial colonies (orphage plaques) which secrete ligands (or modified ligands, or ligandfusions with proteins) are screened for antigen binding on membranes.Either the ligands are bound directly to the membranes (and for exampledetected with labelled antigen), or captured on antigen coated membranes(and detected with reagents specific for ligands). The use of membranesoffers great convenience in screening many clones, and such techniquesare well known in the art.

The screening method may also be greatly facilitated by making proteinfusions with the ligands, for example by introducing a peptide tag whichis recognised by an antibody at the N-terminal or C-terminal and of theligand, or joining the ligand to an enzyme which catalyses theconversion of a colourless substrate to a coloured product. In thelatter case, the binding of antigen may be detected simply by addingsubstrate. Alternatively, for ligands expressed and folded correctlyinside eukaryotic cells, joining of the ligand and a domain of atranscriptional activator such as the GAL4 protein of yeast, and joiningof antigen to the other domain of the GAL4 protein, could form the basisfor screening binding activities, as described by Fields and Song [21].

The preparation of proteins, or even cells with multiple copies of theligands, may improve the avidity of the ligand for immobilised antigen,and hence the sensitivity of the screening method. For example, theligand may be joined to a protein subunit of a multimeric protein, to aphage coat protein or to an outer membrane protein of E. coli such asompA or lamB. Such fusions to phage or bacterial proteins also offerspossibilities of selecting bacteria displaying ligands with antigenbinding activities. For example such bacteria may be precipitated withantigen bound to a solid support, or may be subjected to affinitychromatography, or may be bound to larger cells or particles which havebeen coated wits antigen and sorted using a fluorescence activated cellsorter (FACS). The proteins or peptides fused to the ligands arepreferably encoded by the vector, such that cloning of the ds cDNArepertoire creates the fusion product.

In addition to screening for binding activities of single ligands, itmay be necessary to screen for binding or catalytic activities ofassociated ligands, for example, the associated Ig heavy and light chainvariable domains. For example, repertoires of heavy and light chainvariable genes may be cloned such that two domains are expressedtogether. Only some of the pairs of domains may associate, and only someof these associated pairs may bind to antigen. The repertoires of heavyand light chain variable domains could be cloned such that each domainis paired at random. This approach may be most suitable for isolation ofassociated domains in which the presence of both partners is required toform a cleft. Alternatively, to allow the binding of hapten.Alternatively, since the repertoires of light chain sequences are lessdiverse than those of heavy chains, a small repertoire of light chainvariable domains, for example including representative members of eachfamily of domains, may be combined with a large repertoire of heavychain variable domains.

Preferably however, a repertoire of heavy chain variable domains isscreened first for antigen binding in the absence of the light chainpartner, and then only those heavy chain variable domains binding toantigen are combined with the repertoire of light chain variabledomains. Binding of associated heavy and light chain variable domainsmay be distinguished readily from binding of single domains, for exampleby fusing each domain to a different C-terminal peptide tag which arespecifically recognised by different monoclonal antibodies.

The hierarchical approach of first cloning heavy chain variable domainswith binding activities, then cloning matching light chain variabledomains may be particularly appropriate for the construction ofcatalytic antibodies, as the heavy chain may be screened first forsubstrate binding. A light chain variable domain would then beidentified which is capable of association with the heavy chain, and“catalytic” residues such as cysteine or histidine (or prostheticgroups) would be introduced into the CDRs to stabilise the transitionstate or attack the substrate, as described by Baldwin and Schultz [22].

Although the binding activities of non-covalently associated heavy andlight chain variable domains (Fv fragments) may be screened, suitablefusion proteins may drive the association of the variable domainpartners. Thus Fab fragments are more likely to be associated than theFv fragments, as the heavy chain variable domain is attached to a singleheavy chain constant domain, and the light chain variable domain isattached to a single light chain variable domain, and the two constantdomains associate together.

Alternatively the heavy and light chain variable domains are covalentlylinked together with a peptide, as in the single chain antibodies, orpeptide sequences attached, preferably at the C-terminal end which willassociate through forming cysteine bonds or through non-covalentinteractions, such as the introduction of “leucine zipper” motifs.However, in order to isolate pairs of tightly associated variabledomains, the Fv fragments are preferably used.

The construction of Fv fragments isolated from a repertoire of variableregion genes offers a way of building complete antibodies, and analternative to hybridoma technology. For example by attaching thevariable domains to light or suitable heavy chain constant domains, asappropriate, and expressing the assembled genes in mammalian cells,complete antibodies may be made and should possess natural effectorfunctions, such as complement lysis. This route is particularlyattractive for the construction of human monoclonal antibodies, ashybridoma technology has proved difficult, and for example, althoughhuman peripheral blood lymphocytes can be immortalised with Epstein Barrvirus, such hybridomas tend to secrete low affinity IgM antibodies.

Moreover, it is known that immmunological mechanisms ensure thatlymphocytes do not generally secrete antibodies directed against hostproteins. However it is desirable to make human antibodies directedagainst human proteins, for example to human cell surface markers totreat cancers, or to histocompatibility antigens to treat auto-immunediseases. The construction of human antibodies built from thecombinatorial repertoire of heavy and light chain variable domains mayovercome this problem, as it will allow human antibodies to be builtwith specificities which would normally have been eliminated.

The method also offers a new way of making bispecific antibodies.Antibodies with dual specificity can be made by fusing two hybridomas ofdifferent specificities, so as to make a hybrid antibody with an Fab armof one specificity, and the other Fab arm of a second specificity.However the yields of the bispecific antibody are low, as heavy andlight chains also find the wrong partners. The construction of Fvfragments which are tightly associated should preferentially drive theassociation of the correct pairs of heavy with light chains. (It wouldnot assist in the correct pairing of the two heavy chains with eachother.) The improved production of bispecific antibodies would have avariety of applications in diagnosis and therapy, as is well known.

Thus the invention provides a species specific general oligonucleotideprimer or a mixture of such primers useful for cloning variable domainencoding sequences from animals of that species. The method allows asingle pair or pair of mixtures of species specific general primers tobe used to clone any desired antibody specificity from that species.This eliminates the need to carry out any sequencing of the targetsequence to be cloned and the need to design specific primers for eachspecificity to be recovered.

Furthermore it provides for the construction of repertoires of variablegenes, for the expression of the variable genes directly on cloning, forthe screening of the encoded domains for binding activities and for theassembly of the domains with other variable domains derived from therepertoire.

Thus the use of the method of the present invention will allow for theproduction of heavy chain variable domains with binding activities andvariants of these domains. It allows for the production of monoclonalantibodies and bispecific antibodies, and will provide an alternative tohybridoma technology. For instance, mouse splenic ds mRNA or genomic DNAmay be obtained from a hyperimmunised mouse. This could be cloned usingthe method of the present invention and then the cloned ds DNA insertedinto a suitable expression vector. The expression vector would be usedto transform a host call, for instance a bacterial cell, to enable it toproduce an Fv fragment or a Fab fragment. The Fv or Fab fragment wouldthen be built into a monoclonal antibody by attaching constant domainsand expressing it in mammalian cells.

The present invention is now described, by way of example only, withreference to the accompanying drawings in which:

FIG. 1 shows a schematic representation of the unrearranged andrearranged heavy and light chain variable genes and the location of theprimers;

FIG. 2 shows a schematic representation of the M13-VHPCR1 vector and acloning scheme for amplified heavy chain variable domains;

FIG. 3 shows the sequence of the Ig variable region derived sequences inM13-VHPCR1;

FIG. 4 shows a schematic representation of the M13-VKPCR1 vector and acloning scheme for light chain variable domains;

FIG. 5 shows the sequence of the Ig variable region derived sequences inM13-VKPCR1;

FIG. 6 shows the nucleotide sequences of the heavy and light chainvariable domain encoding sequences of MAb MBr1;

FIG. 7 shows a schematic representation of the pSV-gpt vector (alsoknown as α-Lys 30) which contains a variable region cloned as aHindIII-BamHI fragment, which is excised on introducing the new variableregion. The gene for human IgG1 has also been engineered to remove aBamHI site, such that the BamHI site in the vector is unique;

FIG. 8 shows a schematic representation of the pSV-hygro vector (alsoknown as α-Lys 17). it is derived from pSV gpt vector with the geneencoding mycophenolic acid replaced by a gene coding for hygromycinresistance. The construct contains a variable gene cloned as aHindIII-BamHI fragment which is excised on introducing the new variableregion. The gene for human Cκ has also been engineered to remove a BamHIsite, such that the BamHI site in the vector is unique;

FIG. 9 shows the assembly of the mouse: human MBr1 chimaeric antibody;

FIGS. 10a and 10 b show encoded amino aced sequences of 48 mouserearranged VH genes;

FIG. 11 shows encoded amino acid sequences of human rearranged VH genes;

FIG. 12 shows encoded amino acid sequences of unrearranged human VHgenes;

FIG. 13 shows the sequence of part of the plasmid pSW1: essentially thesequence of a pectate lyase leader linked to VHLYS in pSW1 and cloned asan SphI-EcoRI fragment into pUC19 and the translation of the openreading frame encoding the pectate lyase leader-VHLYS polypeptide beingshown;

FIGS. 14a and 14 b show the sequence of part of the plasmid pSW2:essentially the sequence of a pectate lyase leader linked to VHLYS andto VKLYS, and cloned as an SphI-EcoRI-EcoRI fragment into pUC19 and thetranslation of open reading frames encoding the pectate lyaseleader-VHLYS and pectate lyase leader-VKLYS polypeptides being shown;

FIG. 15 shows the sequence of part of the plasmid pSW1HPOLYMYC which isbased on pSW1 and in which a polylinker sequence has replaced thevariable domain of VHLYS, and acts as a cloning site for amplified VHgenes, and a peptide tag is introduced at the C-terminal end;

FIG. 16 shows the encoded amino acid sequences of two VH domains derivedfrom mouse spleen and having lysozyme binding activity, and comparedwith the VH domain of the D1,3 antibody. The arrows mark the points ofdifference between the two VH domains;

FIG. 17 shows the encoded amino acid sequence of a VH domain derivedfrom human peripheral blood lymphocytes and having lysozyme bindingactivity;

FIG. 18 shows a scheme for generating and cloning mutants of the VHLYSgene, which is compared with the scheme for cloning natural repertoiresof VH genes;

FIG. 19 shows the sequence of part of the vector pSW2HPOLY;

FIG. 20 shows the sequence of part of the vector pSW3 which encodes thetwo linked VHLYS domains;

FIGS. 21a-21 c show the sequence of the VHLYS domain and pelB leadersequence fused to the alkaline phosphatase gene;

FIG. 22 shows the sequence of the vector pSW1VHLYS-VKPOLYMYC forexpression of a repertoire of Vκ light chain variable domains inassociation with the VHLYS domain; and

FIG. 23 shows the sequence of VH domain which is secreted at high levelsfrom E. coli. The differences with VHLYS domain are marked.

PRIMERS

In the Examples described below, the following oligonucleotide primers,or mixed primers were used. Their locations are marked on FIG. 1 andsequences are as follows:

VH1FOR 5′ TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAG 3′; VH1FOR-2 5′TGAGGAGACGGTGACCGTGGTCCCTTGGCCCC 3′; Hu1VHFOR 5′CTTGGTGGAGGCTGAGGAGACGGTGACC 3′; Hu2VHFOR 5′CTTGGTGGAGGCTGAGGAGACGGTGACC 3′; Hu3VHFOR 5′CTTGGTGGATGCTGAGGAGACGGTGACC 3′; Hu4VHFOR 5′CTTGGTGGATGCTGATGAGACGGTGACC 3′; MOJH1FOR 5′TGAGGAGACGGTGACCGTGGTCCCTGCGCCCCAG 3′; MOJH2FOR 5′TGAGGAGACGGTGACCGTGGTGCCTTGGCCCCAG 3′; MOJH3FOR 5′TGCAGAGACGGTGACCAGAGTCCCTTGGCCCCAG 3′; MOJH4FOR 5′TGAGGAGACGGTGACCGAGGTTCCTTGACCCCAG 3′; HUJH1FOR 5′TGAGGAGACGGTGACCAGGGTGCCCTGGCCCCAG 3′; HUJH2FOR 5′TGAGGAGACGGTGACCAGGGTGCCACGGCCCCAG 3′; HUJH4FOR 5′TGAGGAGACGGTGACCAGGGTTCCTTGGCCCCAG 3′; VK1FOR 5′ GTTAGATCTCCAGCTTGGTCCC3′; VK2FOR 5′ CGTTAGATCTCCAGCTTGGTCCC 3′; VK3FOR 5′CCGTTTCAGCTCGAGCTTGGTCCC 3′; MOJK1FOR 5′ CGTTAGATCTCCAGCTTGGTGCC 3′;MOJK3FOR 5′ GGTTAGATCTCCAGTCTGGTCCC 3′; MOJK4FOR 5′CGTTAGATCTCCAACTTTGTCCC 3′; HUJK1FOR 5′ CGTTAGATCTCCACCTTGGTCCC 3′;HUJK3FOR 5′ CGTTAGATCTCCACTTTGGTCCC 3′; HUJK4FOR 5′CGTTAGATCTCCACCTTGGTCCC 3′; HUJK5FOR 5′ CGTTAGATCTCCAGTCGTGTCCC 3′;VH1BACK 5′ AGGT(C/G)(C/A)A(G/A)CTGCAG(G/C)AGTC(T/A)GG 3′; Hu2VHIBACK: 5′CAGGTGCAGCTGCAGCAGTCTGG 3′; HuVHIIBACK: 5′ CAGGTGCAGCTGCAGGAGTCGGG 3′;Hu2VHIIIBACK: 5′ GAGGTGCAGCTGCAGGAGTCTGG 3′; HuVHIVBACK: 5′CAGGTGCAGCTGCAGCAGTCTGG 3′; MOVHIBACK 5′ AGGTGCAGCTGCAGGAGTCAG 3′;MOVHIIABACK 5′ AGGTCCAGCTGCAGCA(G/A)TCTGG 3′; MOVHIIBBACK 5′AGGTCCAACTGCAGCAGCCTGG 3′; MOVHIIBACK 5′ AGGTGAAGCTGCAGGAGTCTGG 3′;VK1BACK 5′ GACATTCAGCTGACCCAGTCTCCA 3′; VK2BACK 5′GACATTGAGCTCACCCAGTCTCCA 3′; MOVKIIABACK 5′ GATGTCAAGCTGACCCAAACTCCA 3′MOVKIIABACK 5′ GATATTCAGCTGACCCAGGATGAA 3′; HuHep1FOR 5′C(A/G)(C/G)TGAGCTCACTGTGTCTCTCGCACA 3′; HuOcta1BACK 5′ CGTGAATATGCAAATAA3′; HuOcta2BACK 5′ AGTAGGAGACATGCAAAT 3′; and HuOcta3BACK 5′CACCACCCACATGCAAAT 3′; VHMUT1 5′ GGAGACGGTGACCGTGGTCCCTTGGCCCCAGTAGTCAAG   NNNNNNNNNNNNCTCTCTGGC 3′ (where N is an    equimolar mixture of T, C,G and A) M13 pRIMER    5′ AACAGCTATGACCATG 3′ (New England Biolabs   *1201)

EXAMPLE 1

Cloning of Mouse Rearranged Variable region genes from hybridomas,assembly of genes encoding chimaeric antibodies and the expression ofantibodies from myeloma cells

VH1FOR is designed to anneal with the 3′ end of the sense strand of anymouse heavy chain variable domain encoding sequence. It contains aBstEII recognition site. VK1FOR is designed to anneal with the 3′ end ofthe sense strand of any mouse kappa-type light chain variable domainencoding sequence and contains a BglII recognition site. VH1BACK isdesigned to anneal with the 3′ end of the antisense strand of any mouseheavy chain variable domain and contains a PstI recognition site.VK1BACK is designed to anneal with the 3′ end of the antisense strand ofany mouse kappa-type light chain variable domain encoding sequence andcontains a PvuII recognition site.

In this Example five mouse hybridomas were used as a source of dsnucleic acid. The hybridomas produce monoclonal antibodies (MAbs)designated MBr1 [23], BW431/26 [24], BW494/32 [25], BW250/183 [24,26]and BW704/152 [27]. MAb MBr1 is particularly interesting in that it isknown to be specific for a saccharide epitope on a human mammarycarcinoma line MCF-7 [28].

Cloning via mRNA

Each of the five hybridomas referred to above was grown up in rollerbottles and about 5×10³ cells of each hybridoma were used to isolateRNA. mRNA was separated from the isolated RNA using oligodT cellulose[29]. First strand cDNA was synthesised according to the proceduredescribed by Maniatis et al. [30] as set out below.

In order to clone the heavy chain variable domain encoding sequence, a50 μl reaction solution which contains 10 μg mRNA, 20 pmole VH1FORprimer, 250 μM each of dATP, dTTP, dCTP and dGTP, 10 mM dithiothreitol(DTT), 100 mM Tris.HCl, 10 mM MgCl₂ and 140 mM KCl, adjusted to pH 8.3was prepared. The reaction solution was heated at 70° C. for ten minutesand allowed to cool to anneal the primer to the 3′ end of the variabledomain encoding sequence in the mRNA. To the reaction solution was thenadded 46 units of reverse transcriptase (Anglian Biotec) and thesolution was then incubated at 42° C. for 1 hour to cause first strandcDNA synthesis.

In order to clone the light chain variable domain encoding sequence, thesame procedure as set out above was used except that the VK1FOR primerwas used in place of the VH1FOR primer.

Amplification from RNA/DNA hybrid

Once the ds RNA/DNA hybrids had been produced, the variable domainencoding sequences were amplified as follows. For heavy chain variabledomain encoding sequence amplification, a 50 μl reaction solutioncontaining 5 μl of the ds RNA/DNA hybrid-containing solution, 25 pmoleeach of VH1FOR and VH1BACK primers, 250 μM of dATP, dTTP, dCTP and dGTP,67 mM Tris.HCl, 17 mM ammonium sulphate, 10 mM MgCl₂, 200 μg/ml gelatineand 2 units Tag polymerase (Cetus) was prepared. The reaction solutionwas overlaid with paraffin oil and subjected to 25 rounds of temperaturecycling using a Techne PHC-1 programmable heating block. Each cycleconsisted of 1 minute and 95° C. (to denature the nucleic acids), 1minute at 30° C. (to anneal the primers to the nucleic acids) and 2minutes at 72° C. (to cause elongation from the primers). After the 25cycles, the reaction solution and the oil were extracted twice withether, once with phenol and once with phenol/CHCl3. Thereafter ds cDNAwas precipitated with ethanol. The precipitated cDNA was then taken upin 50 μl of water and frozen.

The procedure for light chain amplification was exactly as describedabove, except that the VK1FOR and VK1BACK primers were used in place ofthe VH1FOR and VH1BACK primers respectively.

5 μl of each sample of amplified cDNA was fractionated on 2% agarosegels by electrophoresis and stained with ethidium bromide. This showedthat the amplified ds cDNA gave a major band of the expected size (about330 bp). (However the band for VK DNA of MBr1 was very weak. It wastherefore excised from the gel and reamplified in a second round.) Thusby this simple procedure, reasonable quantities of ds DNA encoding thelight and heavy chain variable domains of the five MAbs were produced.

Heavy Chain Vector Construction

A BstEII recognition site was introduced into the vector M13-HuVHNP [31]by site directed mutagenesis [32,33] to produce the ‘vector M13-VHPCR1’(FIGS. 2 and 3).

Each amplified heavy chain variable domain encoding sequence wasdigested with the restriction enzymes PstI and BstEII. The fragmentswere phenol extracted, purified on 2% low melting point agarose gels andforce cloned into vector M13-VHPCR1 which had been digested with PstIand BstEII and purified on an 0.8% agarose gel. Clones containing thevariable domain inserts were identified directly by sequencing [34]using primers based in the 3′ non-coding variable gene in the M13-VHPCR1vector.

There is an internal PstI site in the heavy chain variable domainencoding sequences of BW431/26. This variable domain encoding sequencewas therefore assembled in two steps. The 3′ PstI-BstEII fragment wasfirst cloned into M13-VHPCR1, followed in a second step by the 5′ PstIfragment.

Light Chain Vector Construction

Vector M13mp18 [35] was cut with PvuII and the vector backbone was bluntligated to a synthetic HindIII-BamHI polylinker. Vector M13-HuVKLYS [36]was digested with HindIII and BamHI to isolate the HuVKLYS gene. ThisHindIII-BamHI fragment was then inserted into the HindIII-BamHIpolylinker site to form a vector M13-VKPCR1 which lacks any PvuII sitesin the vector backbone (FIGS. 4 and 5). This vector was prepared in EColi JM110 [22] to avoid dam methylation at the BclI site.

Each amplified light chain variable domain encoding sequence wasdigested with PvuII and BglII. The fragments were phenol extracted,purified on 2% low melting point agarose gels and force cloned intovector M13-VKPCR1 which had been digested with PvuII and BclI, purifiedon an 0.8% agarose gel and treated with calf intestinal phosphatase.Clones containing the light chain variable region inserts wereidentified directly by sequencing [34] using primers based in the 3′non-coding region of the variable domain in the M13-VKPCR1 vector.

The nucleotide sequences of the MBr1 heavy and light chain variabledomains are shown in FIG. 6 with part of the flanking regions of theM13-VHPCR1 and M13-VKPCR1 vectors.

Antibody Expression

The HindIII-BamHI fragment carrying the MBr1 heavy chain variable domainencoding sequence in M13-VHPCR1 was recloned into a pSV-gpt vector withhuman γl constant regions [37] (FIG. 7). The MBr1 light chain variabledomain encoding sequence in M13-VKPCR1 was recloned as a HindIII-BamHIfragment into a pSV vector, PSV-hyg-HuCK with a hygromycin resistancemarker and a human kappa constant domain (FIG. 8). The assembly of thegenes is summarised in FIG. 9.

The vectors thus produced were linearised with PvuI (in the case of thepSV-hygro vectors the PvuI digest is only partial) and cotransfectedinto the non-secreting mouse myeloma line NSO [38] by electroporation[39]. One day after cotransfection, cells were selected in 0.3 μg/mlmycophenolic acid (MPA) and after seven days in 1 μg/ml MPA. After 14days, four wells, each containing one or two major colonies, werescreened by incorporation of ¹⁴C-lysine [40] and the secreted antibodydetected after precipitation with protein-A Sepharose™ (Pharmacia) onSDS-PAGE [41]. The gels were stained, fixed, soaked in a fluorographicreagent, Amplify™ (Amersham), dried and autoradiographed on preflashedfilm at −70° C. for 2 days.

Supernatant was also tested for binding to the mammary carcinoma lineMCF-7 and the colon carcinoma line HT-29, essentially as described byMenard et al. [23], either by an indirect immunoflorescence assay oncell suspensions (using a fluorescein-labelled goat anti-human IgG(Amersham)) or by a solid phase RIA on monolayers of fixed cells (using¹²⁵I-protein A (Amersham)).

It was found that one of the supernatants from the four wells containedsecreted antibody. The chimeric antibody in the supernatant, like theparent mouse MBr1 antibody, was found to bind to MCF-7 cells but not theHT-29 cells, thus showing that the specificity had been properly clonedand expressed.

EXAMPLE 2

Cloning of rearranged variable genes from genomic DNA of mouse spleen

Preparation of DNA from spleen.

The DNA from the mouse spleen was prepared in one of two ways (althoughother ways can be used).

Method 1.

A mouse spleen was cut into two pieces and each piece was put into astandard Eppendorf tube with 200 μl of PBS. The tip of a 1 ml glasspipette was closed and rounded in the blue flame of a Bunsen burner. Thepipette was used to squash the spleen piece in each tube. The cells thusproduced were transferred to a fresh Eppendorf tube and the method wasrepeated three times until the connective tissue of the spleen appearedwhite. Any connective tissue which has been transferred with the cellswas removed using a drawn-out Pasteur pipette. The cells were thenwashed in PBS and distributed into four tubes.

The mouse spleen cells were then sedimented by a 2 minute spin in aMicrocentaur centrifuge at low speed setting. All the supernatant wasaspirated with a drawn out Pasteur pipette. If desired, at this pointthe cell sample can be frozen and stored at −20°C.

To the cell sample (once thawed if it had been frozen) was added 500 μlof water and 5 μl of a 10% solution of NP-40, a non-ionic detergent. Thetube was closed and a hole was punched in the lid. The tube was placedon a boiling water bath for 5 minutes to disrupt the cells and was thencooled on ice for 5 minutes. The tube was then spun for 2 minutes athigh speed to remove cell debris.

The supernatant was transferred to a new tube and to this was added 125μl 5M Nacl and 30 μl 1M MOPS adjusted to pH 7.0. The DNA in thesupernatant was absorbed on a Quiagen 5 tip and purified following themanufacturer's instructions for lambda DNA. After isopropanolprecipitation, the DNA was resuspended in 500 μl water.

Method 2.

This method is based on the technique described in Maniatis et al. [30].A mouse spleen was cut into very fine pieces and put into a 2 ml glasshomogeniser. The cells were then freed from the tissue by several slowup and down strokes with the piston. The cell suspension was made in 500μl phosphate buffered saline (PBS) and transferred to an Eppendorf tube.The cells were then spun for 2 min at low speed in a Microcentaurcentrifuge. This results in a visible separation of white and red cells.The white cells, sedimenting slower, form a layer on top of the redcells. The supernatant was carefully removed and spun to ensure that allthe white cells had sedimented. The layer of white cells was resuspendedin two portions of 500 μl PBS and transferred to another tube.

The white cells were precipitated by spinning in the Microcentaurcentrifuge at low speed for one minute. The cells were washed a furthertwo times with 500 μl PBS, and were finally resuspended in 200 μl PBS.The white cells were added to 2.5 ml 25 mM EDTA and 10 mM Tris.Cl, pH7.4, and vortexed slowly. While vortexing 25 μl 20% SDS was added. Thecells lysed immediately and the solution became viscous and clear. 100μl of 20 mg/ml proteinase K was added and incubated one to three hoursat 50° C.

The sample was extracted with an equal volume of phenol and the samevolume of chloroform, and vortexed. After centrifuging, the aqueousphase was removed and 1/10 volume 3M ammonium acetate was added. Thiswas overlaid with three volumes of cold ethanol and the tube rockedcarefully until the DNA strands became visible. The DNA was spooled outwith a Pasteur pipette, the ethanol allowed to drip off, and the DNAtransferred to 1 ml of 10 mM Tris.Cl pH 7.4, 0.1 mM EDTA in an Eppendorftube. The DNA was allowed to dissolve in the cold overnight on a roller.

Amplification from genomic DNA.

The DNA solution was diluted 1/10 in water and boiled for 5 min prior tousing the polymerase chain reaction (PCR). For each PCR reaction,typically 50-200 ng of DNA were used.

The heavy and light chain variable domain encoding sequences in thegenomic DNA isolated from the human PBL or the mouse spleen cells wasthen amplified and cloned using the general protocol described in thefirst two paragraphs of the section headed “Amplification from RNA/DNAHybrid” in Example 1, except that during the annealing part of eachcycle, the temperature was held at 65° C. and that 30 cycles were used.Furthermore, to minimise the annealing between the 3′ ends of the twoprimers, the sample was first heated to 95° C., then annealed at 65° C.,and only then was the Taq polymerase added. At the end of the 30 cycles,the reaction mixture was held at 60° C. for five minutes to ensure thatcomplete elongation and renaturation of the amplified fragments hadtaken place.

The primers used to amplify the mouse spleen genomic DNA were VH1FOR andVH1BACK, for the heavy chain variable domain and VK2FOR and VK1BACK, forthe light chain variable domain. (VK2FOR only differs from VK1FOR inthat it has an extra C residue on the 5′ end.)

Other sets of primers, designed to optimise annealing with differentfamilies of mouse VH and Vκ genes were devised and used in mixtures withthe primers above. For example, mixtures of VK1FOR, MOJK1FOR, MOJK3FORand MOJK4FOR were used as forward primers and mixtures of VK1BACK,MOVKIIABACK and MOVKIIBBACK as back primers for amplification of Vκgenes. Likewise mixtures of VH1FOR, MOJH1FOR, MOJH2FOR, MOJH3FOR andMOJH4FOR were used as forward primers and mixtures of VH1BACK,MOVHIBACK, MOVHIIABACK, MOVHIIBBACK, MOVHIIIBACK were used as backwardprimers for amplification of VH genes.

All these heavy chain FOR primers referred to above contain a BstEIIsite and all the BACK primers referred to above contain a PstI site.These light chain FOR and BACK primers referred to above all containBglII and PvuII sites respectively. Light chain primers (VK3FOR andVK2BACK) were also devised which utilised different restriction sites,SacI and XhoI.

Typically all these primers yielded amplified DNA of the correct size ongel electrophoresis, although other bands were also present. However, aproblem was identified in which the 5′ and 3′ ends of the forward andbackward primers for the VH genes were partially complementary, and thiscould yield a major band of “primer-dimer” in which the twooligonucleotides prime on each other. For this reason an improvedforward primer, VH1FOR-2 was devised in which the two 3′ nucleotideswere removed from VH1FOR.

Thus, the preferred amplification conditions for mouse VH genes are asfollows: the sample was made in a volume of 50 −100 μl, 50-100 ng ofDNA, VH1FOR-2 and VH1BACK primers (25 pmole of each), 250 μM of eachdeoxynucleotide triphosphate, 10 mM Tris.HCl, pH 8.8, 50 mM KCl, 1.5 mMMgCl₂, and 100 μg/ml gelatin. The sample was overlaid with paraffin oil,heated to 95° C. for 2 min, 65° C. for 2 min, and then to 72° C.: taqpolymerase was added after the sample had reached the elongationtemperature and the reaction continued for 2 min at 72° C. The samplewas subjected to a further 29 rounds of temperature cycling using theTechne PHC-1 programmable heating block.

The preferred amplification conditions for mouse Vk genes from genomicDNA are as follows: the sample treated as above except with Vκ primers,for example VK3FOR and VK2BACK, and using a cycle of 94° C. for oneminute, 60° C. for one minute and 72° C. for one minute.

The conditions which were devised for genomic DNA are also suitable foramplification from the cDNA derived from mRNA from mouse spleen or mousehybridoma.

Cloning and analysis of variable region genes

The reaction mixture was then extracted twice with 40 μl ofwater-saturated diethyl ether. This was followed by a standard phenolextraction and ethanol precipitation as described in Example 1. The DNApellet was then dissolved in 100 μl 10 mM Tris.Cl, 0.1 mM EDTA.

Each reaction mixture containing a light chain variable domain encodingsequence was digested with SacI and XhoI (or with PvuII and BglII) toenable it to be ligated into a suitable expression vector. Each reactionmixture containing a heavy chain variable domain encoding sequence wasdigested with PstI and BstEII for the same purpose.

The heavy chain variable genes isolated as above from a mousehyperimmunised with lysozyme were cloned into M13VHPCR1 vector andsequenced. The complete sequences of 48 VH gene clones were determined(FIG. 10). All but two of the mouse VH gene families were represented,with frequencies of: VA (1), IIIC (1), IIIB (8), IIIA (3), IIB (17), IIA(2), IB (12), IA (4). In 30 clones, the D segments could be assigned tofamilies SP2 (14), FL16 (11) and Q52 (5), and in 38 clones the JHminigenes to families JH1 (3), JH2 (7), JH3 (14) and JH4 (14). Thedifferent sequences of CDR3 marked out each of the 48 clones as unique.Nine pseudogenes and 16 unproductive rearrangements were identified. Ofthe clones sequenced, 27 have open reading frames.

Thus the method is capable of generating a diverse repertoire of heavychain variable genes from mouse spleen DNA.

EXAMPLE 3

Cloning of rearranged variable genes from mRNA from human peripheralblood lymphocytes

Preparation of mRNA.

Human peripheral blood lymphocytes were purified and mRNA prepareddirectly (Method 1), or mRNA was prepared after addition of Epstein Barrvirus (Method 2).

Method 1.

20 ml of heparinised human blood from a healthy volunteer was dilutedwith an equal volume of phosphate buffered saline (PBS) and distributedequally into 50 ml Falcon tubes. The blood was then underlayed with 15ml Ficoll Hypaque (Pharmacia 10-A-001-07). To separate the lymphocytesfrom the red blood cells, the tubes were spun for 10 minutes at 1800 rpmat room temperature in an IEC Centra 3E table centrifuge. The peripheralblood lymphocytes (PBL) were then collected from the interphase byaspiration with a Pasteur pipette. The cells were diluted with an equalvolume of PBS and spun again at 1500 rpm for 15 minutes. The supernatantwas aspirated, the cell pellet was resuspended in 1 ml PBS and the cellswere distributed into two Eppendorf tubes.

Method 2.

40 ml human blood from a patient with HIV in the pre-AIDS condition waslayered on Ficoll to separate the white cells (see Method 1 above). Thewhite cells were then incubated in tissue culture medium for 4-5 days.On day 3, they were infected with Epstein Barr virus. The cells werepelleted (approx 2×10⁷ cells) and washed in PBS.

The cells were pelleted again and lysed with 7 ml 5M guanidineisothiocyanate, 50 mM Tris, 10 mM EDTA, 0.1 mM dithiothreitol. The cellswere vortexed vigorously and 7 volumes of 4M LiCl added. The mixture wasincubated at 4° C. for 15-20 hrs. The suspension was spun and thesupernatant resuspended in 3M LiCl and centrifuged again. The pellet wasdissolved in 2 ml 0.1% SDS, 10 mM Tris HCl and 1 mM EDTA. The suspensionwas frozen at −20° C., and thawed by vortexing for 20 s every 10 min for45 min. A large white pellet was left behind and the clear supernatantwas extracted with phenol chloroform, then with chloroform. The RNA wasprecipitated by adding 1/10 volume 3M sodium acetate and 2 vol ethanolaid leaving overnight at −20° C. The pellet was suspended in 0.2 mlwater and reprecipitated with ethanol. Aliquots for cDNA synthesis weretaken from the ethanol precipitate which had been vortexed to create afine suspension.

100 μl of the suspension was precipitated and dissolved in 20 μl waterfor cDNA synthesis [30] using 10 pmole of a HUFOR primer (see below) infinal volume of 50 μl. A sample of 5 μl of the cDNA was amplified as inExample 2 except using the primers for the human VH gene families (seebelow) using a cycle of 95° C., 60° C. and 72° C.

The back primers for the amplification of human DNA were designed tomatch the available human heavy and light chain sequences, in which thedifferent families have slightly different nucleotide sequences at the5′ end. Thus for the human VH genes, the primers Hu2VHIBACK, HuVHIIBACK,Hu2VHIIIBACK and HuVH1VBACK were designed as back primers, and HUJH1FOR,HUJH2FOR and HUJH4FOR as forward primers based entirely in the variablegene. Another set of forward primers Hu1VHFOR, Hu2VHFOR, Hu3VHFOR, andHu4VHFOR was also used, which were designed to match the human J-regionsand the 5′ end of the constant regions of different human isotopes.

Using sets of these primers it was possible to demonstrate a band ofamplified ds cDNA by gel electrophoresis.

One such experiment was analysed in detail to establish whether therewas a diverse repertoire in a patient with HIV infection. It is knownthat during the course of AIDS, that T-cells and also antibodies aregreatly diminished in the blood. Presumably the repertoire oflymphocytes is also diminished. In this experiment, for the forwardpriming, an equimolar mixture of primers Hu1VHFOR, Hu2VHFOR, Hu3VHFOR,and Hu4VHFOR (in PCR 25 pmole of primer 5′ ends) was used. For the backpriming, the primers Hu2VHIBACK, HuVHIIBACK, Hu2VHIIIBACK and HuVH1VBACKwere used separately in four separate primings. The amplified DNA fromthe separate primings was then pooled, digested with restriction enzymesPstI and BstEII as above, and then cloned into the vector M13VHPCR1 forsequencing. The sequences reveal a diverse repertoire (FIG. 11) at thisstage of the disease.

For human Vκ genes the primers HuJK1FOR, HUJK3FOR, HUJK4FOR and HUJK5FORwere used as forward primers and VK1BACK as back primer. Using theseprimers it was possible to see a band of amplified ds cDNA of thecorrect size by gel electrophoresis.

EXAMPLE 4

Cloning of unrearranged variable gene genomic DNA from human peripheralblood lymphocytes

Human peripheral blood lymphocytes of a patient with non-Hodgkinslymphoma were prepared as in Example 3 (Method 1). The genomic DNA wasprepared from the PBL using the technique described in Example 2 (Method2). The VH region in the isolated genonic DNA was then amplified andcloned using the general protocol described in the first two paragraphsof the section headed “Amplification from RNA/DNA hybrid” in Example 1above, except that during the annealing part of each cycle, thetemperature was held at 55° C. and that 30 cycles were used. At the endof the 30 cycles, the reaction mixture was held at 60° C. for fiveminutes to ensure that complete elongation and renaturation of theamplified fragments had taken place.

The forward primer used was HuHep1FOR, which contains a SacI site. Thisprimer is designed to anneal to the 3′ end of the unrearranged human VHregion gene, and in particular includes a sequence complementary to thelast three codons in the VH region gene and nine nucleotides downstreamof these three codons.

As the back primer, an equimolar mixture of HuOcta1BACK, HuOcta2BACK andHuOcta3BACK was used. These primers anneal to a sequence in the promoterregion of the genomic DNA VH gene (see FIG. 1). 5 μl of the amplifiedDNA was checked on 2% agarose gels in TBE buffer and stained withethidium bromide. A double band was seen of about 620 nucleotides whichcorresponds to the size expected for the unrearranged VH gene. The dscDNA was digested with SacI and cloned into an M13 vector forsequencing. Although there are some sequences which are identical, arange of different unrearranged human VH genes were identified (FIG.12).

EXAMPLE 5

Cloning Variable Domains with Binding Activities from a Hybridoma

The heavy chain variable domain (VHLYS) of the D1.3 (anti-lysozyme)antibody was cloned into a vector similar to that described previously[42] but under the control of the lac z promoter, such that the VHLYSdomain is attached to a pelB leader sequence for export into theperiplasm. The vector was constructed by synthesis of the pelB leadersequence [43], using overlapping oligonucleotides, and cloning into apUC 19 vector [35]. The VHLYS domain of the D1.3 antibody was derivedfrom a cDNA clone [44] and the construct (pSW1) sequenced (FIG. 13).

To express both heavy and light chain variable domains together, thelight chair variable region (VKLYS) of the D1.3 antibody was introducedinto the pSW1 vector, with a pelb signal sequence to give the constructpSW2 (FIG. 14)

A strain of E. coli (BMH71-18) [45] was then transformed [46,47] withthe plasmid pSW1 or pSW2, and colonies resistant to ampicillin (100μg/ml) were selected on a rich (2×TY=per liter of water, 16 gBacto-tryptone, 10 g yeast extract, 5 g NaCl) plate which contained 1%glucose to repress the expression of variable domain(s) by cataboliterepression.

The colonies were inoculated into 50 ml 2×TY (with 1% glucose and 100μg/ml ampicillin) and grown in flasks at 37° C. with shaking for 12-16hr. The cells were centrifuged, the pellet washed twice wish 50 mMsodium chloride, resuspended in 2×TY medium containing 100 μg/mlampicillin and the inducer IPTG (1 mM) and grown for a further 30 hrs at37° C. The cells were centrifuged and the supernatant was passed througha Nalgene filter (0.45 μm) and then down a 1-5 ml lysozyme-Sepharoseaffinity column. (The column was derived by coupling lysozyme at 10mg/ml to CNBr activated Sepharose.) The column was first washed withphosphate buffered saline (PBS), then with 50 mM diethylamine to elutethe VHLYS domain (from pSW1, or VHLYS in association with VKLYS (frompSW2).

The VKLYS and VKLYS domains were identified by SDS polyacrylamideelectrophoresis as the correct size. In addition, N-terminal sequencedetermination of VHLYS and VKLYS isolated from a polyacrylamide gelshowed that the signal peptide had been produced correctly. Thus boththe Fv fragment and the VHLYS domains are able to bind to the lysozymeaffinity column, suggesting that both retain at least some of theaffinity of the original antibody.

The size of the VHLYS domain was compared by FPLC with that of the Fvfragment on Superose 12. This indicates that the VHLYS domain is amonomer. The bending of the VHLYS and Fv fragment to lysozyme waschecked by ELISA, and equilibrium and rapid reaction studies werecarried out using fluorescence quench.

The ELISA for lysozyme binding was undertaken as follows:

(1) The plates (Dynatech Immulon) were coated with 200 μl per well of300 μg/ml lysozyme in 50 mM NaHCO₃, pH 9.6 overnight at roomtemperature;

(2) The wells were rinsed with three washes of PBS, and blocked with 300μl per well of 1% Sainsbury's instant dried skimmed milk powder in PBSfor 2 hours at 37° C.;

(3) The wells were rinsed with three washes of PBS and 200 μl of VHLYSor Fv fragment (VHLYS associated with VKLYS) were added and incubatedfor 2 hours at room temperature;

(4) The wells were washed three tines with 0.05% Tween 20 in PBS andthen three tires with PBS to remove detergent;

(5) 200 μl of a suitable dilution (1:100) of rabbit polyclonal antiseraraised against the FV fragment in 2% skimmed milk powder in PBS wasadded to each well and incubated at room temperature for 2 hours;

(6) Washes were repeated as in (4);

(7) 200 μl of a suitable dilution (1:1000) of goat anti-rabbit antibody(ICN Immunochemicals) coupled to horse radish peroxidase, in 2% skimmedmilk powder in PBS, was added to each well and incubated at roomtemperature for 1 hour;

(8) Washes were repeated as in (4); and

(9) 200 μl 2,2′azino-bis(3-ethylbenzthiazolinesulphonic acid) [Sigma](0.55 mg/ml, with 1 μl 20% hydrogen peroxide: water per 10 ml) was addedto each well and the colour allowed to develop for up to 10 minutes atroom temperature.

The reaction was stopped by adding 0.05% sodium azide in 50 mM citricaced pH 4.3. ELISA plates were read in a Titertek Multiscan platereader. Supernatant from the induced bacterial cultures of both pSW1(VHLYS domain) or pSW2 (Fv fragment) was found to bind to lysozyme inthe ELISA.

The purified VHLYS and Fv fragments were titrated with lysozyme usingfluorescence quench (Perkin Elmer LS5B Luminescence Spectrometer) tomeasure the stoichiometry of binding and the affinity constant forlysozyme [48,49]. The titration of the Fv fragment at a concentration of30 nM indicates a dissociation constant of 2.8 nM using a Scatchardanalysis.

A similar analysis using fluorescence quench and a Scatchard plot wascarried out for VHLYS, at a VHLYS concentration of 100 nM. Thestoichiometry of antigen binding is about 1 mole of lysozyme per mole ofVHLYS (calculated from plot). (The concentration of VH domains wascalculated from optical density at 280 nM using the typical extinctioncoefficient for complete immunoglobulins.) Due to possible errors inmeasuring low optical densities and the assumption about the extinctioncoefficient, the stoichiometry was also measured more carefully. VHLYSwas titrated with lysozyme as above using fluorescence quench. Todetermine the concentration of VHLYS a sample of the stock solution wasremoved, a known amount of norleucine added, and the sample subjected toquantitative amino acid analysis. This showed a stoichiometry of 1.2mole of lysozyme per mole of VHLYS domain. The dissociation constant wascalculated as about 12 nM.

The on-rates for VHLYS and Fv fragments with lysozyme were determined bystopped-flow analysis (HI Tech Stop Flow SHU machine) under pseudo-firstorder conditions with the fragment at a ten fold higher concentrationthan lysozyme [50]. The concentration of lysozyme binding sites wasfirst measured by titration with lysozyme using fluorescence quench asabove. The on rates were calculated per mole of binding site (ratherthan amount of VHLYS protein). The on-rate for the Fv fragment was foundto be 2.2×10⁶ M⁻¹ s⁻¹ at 25° C. The on-rate for the VHLYS fragment foundto be 3.8×10⁶ M⁻¹ s⁻¹ and the off-rate 0.075 s⁻¹ at 20° C. Thecalculated affinity constant is 19 nM. Thus the VHLYS binds to lysozymewith a dissociation constant of about 19 nM, compared with that of theFV of 3 nM.

EXAMPLE 6

Cloning complete variable domains with binding activities from mRNA orDNA of antibody-secreting cells

A mouse was immunised with hen egg white lysozyme (100 μg i.p. day 1 incomplete Freunds adjuvant), after 14 days immunised i.p. again with 100μg lysozyme with incomplete Freunds adjuvant, and on day 35 i.v. with 50μg lysozyme in saline. On day 39, spleen was harvested. A second mousewas immunised with keyhole limpet haemocyanin (KLH) in a similar way.The DNA was prepared from the spleen according to Example 2 (Method 2).The ASH genes were amplified according to the preferred method inExample 2.

Human peripheral blood lymphocytes from a patient infected with HIV wereprepared as in Example 3 (Method 2) and mRNA prepared. The VH genes wereamplified according to the method described in Example 3, using primersdesigned for human VH gene families.

After the PCR, the reaction mixture and oil were extracted twice withether, once with phenol and once with phenol/CHCl₃. The double strandedDNA was then taken up in 50 μl of water and frozen. 5 μl was digestedwith PstI and BstEII (encoded within the amplification primers) andloaded on an agarose gel for electrophoresis. The band of amplified DNAat about 350 bp was extracted.

Expression of anti-lysozyme activities

The repertoire of amplified heavy chain variable domains (from mouseimmunised with lysozyme and from human PBLs) was then cloned directlyinto the expression vector pSW1HPOLYMYC. This vector is derived frompSW1 except that the VHLYS gene has been removed and replaced by apolylinker restriction site. A sequence encoding a peptide tag wasinserted (FIG. 15). Colonies were toothpicked into 1 ml cultures. Afterinduction (see Example 5 for details), 10 μl of the supernatant fromfourteen 1 ml cultures was loaded on SDS-PAGE gels and the proteinstransferred electrophoretically to nitrocellulose. The blot was probedwith antibody 9E10 directed against the peptide tag.

The probing was undertaken as follows. The nitrocellulose filter wasincubated in 3% bovine serum albumin (BSA)/TBS buffer for 20 min (10×TBSbuffer is 100 mM Tris.HCl, pH 7.4, 9% w/v NaCl). The filter wasincubated in a suitable dilution of antibody 9E10 (about 1/500) in 3%BSA/TBS for 1-4 hrs. After three washes in TBS (100 ml per wash, eachwash for 10 min), the filter was incubated with 1:500 dilution ofanti-mouse antibody (peroxidase conjugated anti-mouse Ig (Dakopats)) in3% BSA/TBS for 1-2 hrs. After three washes in TBS and 0.1% Triton X-100(about 100 ml per wash, each wash for 10 min), a solution containing 10ml chloronapthol in methanol (3 mg/ml), 40 ml TBS and 50 μl hydrogenperoxide solution was added over the blot and allowed to react for up to10 min. The substrate was washed out with excess water. The blotrevealed bands similar in mobility to VHLYSMYC on the Western blot,showing that other VH domains could be expressed.

Colonies were then toothpicked individually into wells of an ELISA plate(200 μl) for growth and induction. They were assayed for lysozymebinding with the 9E10 antibody (as in Examples 5 and 7). Wells withlysozyme-binding activity were identified. Two positive wells (of 200)were identified from the amplified mouse spleen DNA and one well fromthe human cDNA. The heavy chain variable domains were purified on acolumn of lysozyme-Sepharose. The affinity for lysozyme of the cloneswas estimated by fluorescence quench titration as >50 nM. The affinitiesof the two clones (VH3 and VH8) derived from the mouse genes were alsoestimated by stop flow analysis (ratio of k_(on)/k_(off)) as 12 nM and27 nM respectively. Thus both these clones have a comparable affinity tothe VHLYS domain. The encoded amino acid sequences of of VH3 and VH8 aregiven in FIG. 16, and that of the human variable domain in FIG. 17.

A library of VH domains made from the mouse immunised with lysozyme wasscreened for both lysozyme and keyhole limpet haemocyanin (KLH) bindingactivities. Two thousand colonies were toothpicked in groups of fiveinto wells of ELISA plates, and the supernatants tested for binding tolysozyme coated plates and separately to KLH coated plates. Twenty onesupernatants were shown to have lysozyme binding activities and two tohave KLH binding activities. A second expression library, prepared froma mouse immunised with KLH was screened as above. Fourteen supernatantshad KLH binding activities and a single supernatant had lysozyme bindingactivity.

This shows that antigen binding activities can be prepared from singleVH domains, and that immunisation facilitates the isolation of thesedomains.

EXAMPLE 7

Cloning variable domains with binding activities by mutagenesis.

Taking a single rearranges VH gene, it may be possible to deriveentirely new antigen binding activities by extensively mutating each ofthe CDRs. The mutagenesis might be entirely random, or be derived frompre-existing repertoires of CDRs. Thus a repertoire of CDR3s might beprepared as in the preceding examples by using “universal” primers basedin the flanking sequences, and likewise repertoires of the other CDRs(singly or in combination). The CDR repertoires could be stitched intoplace in the flanking framework regions by a variety of recombinant DNAtechniques.

CDR3 appears to be the most promising region for mutagenesis as CDR3 ismore variable in size and sequence than CDRs 1 and 2. This region wouldbe expected to make a major contribution to antigen binding. The heavychain variable region (VHLYS) of the anti-lysozyme antibody D1.3 isknown to make several important contacts in the CDR3 region.

Multiple mutations were made in CDR3. The polymerase chain reaction(PCR) and a highly degenerate primer were used to make the mutations andby this means the original sequence of CDR3 was destroyed. (It wouldalso have been possible to construct the mutations in CDR3 by cloning amixed oligonucleotide duplex into restriction sites flanking the CDR orby other methods of site-directed mutagenesis). Mutants expressing heavychain variable domains with affinities for lysozyme were screened andthose with improved affinities or new specificities were identified.

The source of the heavy chain variable domain was an M13 vectorcontaining the VHLYS gene. The body of the sequence encoding thevariable region was amplified using the polymerase chain reaction (PCR)with the mutagenic primer VHMUT1 based in CDR3 and the M13 primer whichis based in the M13 vector backbone. The mutagenic primer hypermutatesthe central four residues of CDR3 (Arg-Asp-Tyr-Arg). The PCR was carriedout for 25 cycles on a Techne PHC-1 programmable heat block using 100 ngsingle stranded M13mp19SW0 template, with 25 pmol of VHMUT1 and the M13primer, 0.5 mM each dNTP, 67 mM Tris.HCl, pH 8.8, 10 mM MgCl2, 17 mM(NH₄)₂SO₄, 200 μg/ml gelatine and 2.5 units Taq polymerase in a finalvolume of 50 μl. The temperature regime was 95° C. for 1.5 min, 25° C.for 1.5 min and 72° C. for 3 min (However a range of PCR conditionscould be used). The reaction products were extracted withphenol/chloroform, precipitated with ethanol and resuspended in 10 mMTris. HCl and 0.1 mM EDTA, pH 8.0.

The products from the PCR were digested with PstI and BstEII andpurified on a 1.5% LGT agarose gel in Tris acetate buffer usingGeneclean (Bio 101, LaJolla). The gel purified band was ligated intopSW2HPOLY (FIG. 19). (This vector is related to pSW2 except that thebody of the VHLYS gene has been replaced by a polylinker.) The vectorwas first digested with BstEII and PstI and treated with calf-intestinalphosphatase. Aliquots of the reaction mix were used to transform E. coliBMH 71-18 to ampicillin resistance. Colonies were selected on ampicillin(100 μg/ml) rich plates containing glucose at 0.8% w/v.

Colonies resulting from transfection were picked in pools of five intotwo 96 well Corning microtitre plates, containing 200 μl 2×TY medium and100 μl TY medium, 100 μg/ml ampicillin and 1% glucose. The colonies weregrown for 24 hours at 37° C. and then cells were washed twice in 200 μl50 mM NaCl, pelleting the cells in an IEC Centra-3 bench top centrifugewith microtitre plate head fitting. Plates were spun at 2,500 rpm for 10min at room temperature. Cells were resuspended in 200 μl 2×TY, 100μg/ml ampicillin and 1 mM IPTG (Sigma) to induce expression, and grownfor a further 24 hr.

Cells were spun down and the supernatants used in ELISA with lysozymecoated plates and anti-idiotypic sera (raised in rabbits against the Fvfragment of the D1.3 antibody). Bound anti-idiotypic serum was detectedusing horse radish peroxidase conjugated to anti-rabbit sera (ICNImmunochemicals). Seven of the wells gave a positive result in theELISA. These pools were restreaked for single colonies which werepicked, grown up, induced in microtitre plates and rescreened in theELISA as above. Positive clones were grown up at the 50 ml scale andexpression was induced. Culture supernatants were purified as in Example5 on columns of lysozyme-Secharose and eluates analysed on SDS-PAGE andstaining with Page Blue 90 (BDH). On elution of the column withdiethylamine, bands corresponding to the VHLYS mutant domains wereidentified, but none to the VKLYS domains. This suggested that althoughthe mutant domains could bind to lysozyme, they could no longerassociate with the VKYLS domains.

For seven clones giving a positive reaction in ELISA, plasmids wereprepared and the VKLYS gene excised by cutting with EcoRI andreligating. Thus the plasmids should only direct the expression of theVHLYS mutants. 1.5 ml cultures were grown and induced for expression asabove. The cells were spun down and supernatant shown to bind lysozymeas above. (Alternatively the amplified mutant VKLYS genes could havebeen cloned directly into the pSW1HPOLY vector for expression of themutant activities in the absence of VKLYS.)

An ELISA method was devised in which the activities of bacterialsupernatants for binding of lysozyme (or KLH) were compared. Firstly avector was devised for tagging of the VH domains at its C-terminalregion with a peptide from the c-myc protein which is recognised by amonoclonal antibody 9E10. The vector was derived from pSW1 by a BstEIIand SmaI double digest, and ligation of an oligonucleotide duplex madefrom

5′ GTC ACC GTC TCC TCA GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT TAATAA 3′ and

5′ TTA TTA ATT CAG ATC CTC TTC TGA GAT GAG TTT TTG TTC TGA GGA GAC G 3′.

The VHLYSMYC protein domain expressed after induction was shown to bindto lysozyme and to the 9E10 antibody by ELISA as follows:

(1) Falcon (3912) flat bottomed wells were coated with 180 μl lysozyme(3 mg/ml) or KLH (50 μg/ml) per well in 50 mM NaHCO3, pH 9.6, and leftto stand at room temperature overnight;

(2) The wells were washed with PBS and blocked for 2 hrs at 37° C. with200 μl 2% Sainsbury's instant dried skimmed milk powder in PBS per well;

(3) The Blocking solution was discarded, and the walls washed out withPBS (3 washes) and 150 μl test solution (supernatant or purified taggeddomain) pipetted into each well. The sample was incubated at 37° C. for2 hrs;

(4) The test solution was discarded, and the wells washed out with PBS(3 washes). 100 μl of 4 μg/ml purified 9E10 antibody in 2% Sainsbury'sinstant dried skimmed milk powder in PBS was added, and incubated at 37°C. for 2 hrs;

(5) The 9E10 antibody was discarded, the wells washed with PBS (3washes). 100 μl of 1/500 dilution of anti-mouse antibody (peroxidaseconjugated anti-mouse Ig (Dakopats)) was added and incubated at 37° C.for 2 hrs;

(6) The second antibody was discarded and wells washed three times withPBS; and

(7) 100 μl 2,2′azino-bis(3-ethylbenzthiazolinesulphonic acid) [Sigma](0.55 mg/ml, with 1 μl 20% hydrogen peroxide: water per 10 ml) was addedto each well and the colour allowed to develop for up to 10 minutes atroom temperature.

The reaction was stopped by adding 0.05% sodium azide in 50 mM citricacid, pH 4.3. ELISA plates were read in an Titertek Multiscan platereader.

The activities of the mutant supernatants were compared with VHLYSsupernatant by competition with the VHLYSMYC domain for binding tolysozyme. The results show that supernatant from clone VHLYSMUT59 ismore effective than wild type VHLYS supernatant in competing forVHLYSMYC. Furthermore, Western blots of SDS-PAGE aliquots of supernatantfrom the VHLYS and VHLYSMUT59 domain (using anti-Fv antisera) indicatedcomparable amounts of the two samples. Thus assuming identical amountsof VHLYS and VHLYSMUT59, the affinity of the mutant appears to begreater than that of the VHLYS domain.

To check the affinity of the VHLYSMUT59 domain directly, the clone wasgrown at the 1l scale and 200-300 μg purified on lysozyme-Sepharose asin Example 5. By fluorescence quench titration of samples of VHLYS andVHLYSMUT59, the number of binding sites for lysozyme were determined.The samples of VHLYS and VHLYSMUT59 were then compared in thecompetition ELISA with VHLYSMYC over two orders of magnitude. In thecompetition assay each microtitre well contained a constant amount ofVHLYSMYC (approximately 0.6 μg VHLYSMYC). Varying amounts of VHLYS orVHLYSMUT59 (3.8 μM in lysozyme binding sites) were added (0.166-25 μl).The final volume and buffer concentration in all wells was constant.9E10 (anti-myc) antibody was used to quantitate bound VHLYSMYC in eachassay well. The % inhibition of VHLYSMYC binding was calculated for eachaddition of VHLYS or VHLYSMUT59, after subtraction of backgroundbinding. Assays were carried out in duplicate. The results indicate thatVHLYSMUT59 has a higher affinity for lysozyme than VHLYS.

The VHLYSMUT59 gene was sequenced (after recloning into M13) and shownto be identical to the VHLYS gene except for the central residues ofCDR3 (Arg-Asp-Tyr-Arg). These were replaced by Thr-Gln-Arg-Pro: (encodedby ACACAAAGGCCA).

A library of 2000 mutant VH clones was screened for lysozyme and alsofor KLH binding (toothpicking 5 colonies per well as described inExample 6). Nineteen supernatants were identified with lysozyme bindingactivities and four with KLH binding activities. This indicates that newspecificites and improved affinities can be derived by making a randomrepertoire of CDR3.

EXAMPLE 8

Construction and expression of double domain for lysozyme binding.

The finding that single domains have excellent binding activities shouldallow the construction of strings of domains (concatamers). Thus,multiple specificities could be built into the sane molecule, allowingbinding to different epitopes spaced apart by the distance betweendomain heads. Flexible linker regions could be built to space out thedomains. In principle such molecules could be devised to haveexceptional specificity and affinity.

Two copies of the cloned heavy chain variable gene of the D1.3 antibodywere linked by a nucleotide sequence encoding a flexible linkerGly-Gly-Gly-Ala-Pro-Ala-Ala-Ala-Pro-Ala-Gly-Gly-Gly- (by several stepsof cutting, pasting and site directed mutagenesis) to yield the plasmidpSW3 (FIG. 20). The expression was driven by a lacz promoter and theprotein was secreted into the periplasm via a pelb leader sequence (asdescribed in Example 5 for expression of pSW1 and pSW2). The proteincould be purified to homogeneity on a lysozyme affinity column. On SDSpolyacrylamide gels, it gave a band of the right size (molecular weightabout 26,000). The protein also bound strongly to lysozyme as detectedby ELISA (see Example 5) using anti-idiotypic antiserum directed againstthe Fv fragment of the D1.3 antibody to detect the protein. Thus, suchconstructs are readily made and secreted and at least one of the domainsbinds to lysozyme.

EXAMPLE 9

Introduction of cysteine residue at C-terminal end of VHLYS

A cysteine residue was introduced at the C-terminus of the VHLYS domainin the vector pSW2. The cysteine was introduced by cleavage of thevector with the restriction enzymes BstI and SmaI (which excises theC-terminal portion of the J segment) and ligation of a shortoligonucleotide duplex

5′ GTC ACC GTC TCC TCA TGT TAA TAA 3′ and

5′ TTA TTA ACA TGA GGA GAC G 3′.

By purification on an affinity column of lysozyme Sepharose it was shownthat the VHLYS-Cys domain was expressed in association with the VKLYSvariable domain, but the overall yields were much lower than the wildtype Fv fragment. Comparison of non-reducing and reducing SDSpolyacrylamide gels of the purified Fv-Cys protein indicated that thetwo VH-Cys domains had become linked through the introduced cysteineresidue.

EXAMPLE 10

Linking of VH domain with enzyme

Linking of enzyme activities to VH domains should be possible by eithercloning the enzyme on either the N-terminal or the C-terminal side ofthe VH domain. Since both partners must be active, it may be necessaryto design a suitable linker (see Example 8) between the two domains. Forsecretion of the VH-enzyme fusion, it would be preferable to utilize anenzyme which is usually secreted. In FIG. 21, there is shown thesequence of a fusion of a VH domain with alkaline phosphatase. Thealkaline phosphatase gene was cloned from a plasmid carrying the E. colialkaline phosphatase gene in a plasmid pEK48 [51] using the polymerasechain reaction. The gene was amplified with the primers

5′ CAC CAC GGT CAC CGT CTC CTC ACG GAC ACC AGA AAT GCC TGT TCT G 3′ and5′ GCG AAA ATT CAC TCC CGG GCG CGG TTT TAT TTC 3′.

The gene was introduced into the vector pSW1 by cutting at BstEII andSmaI. The construction (FIG. 21) was expressed in E. coli strainBMH71-18 as in Example 5 and screened for phosphatase activity using 1mg/ml p-nitrophenylphosphate as substrate in 10 mM diethanolamine and0.5 mM MgCl², pH 9.5) and also on SDS polyacrylamide gels which had beenWestern blotted (detecting with anti-idiotypic antiserum). No evidencewas found for the secretion of the linked VHLYS-alkaline phosphatase asdetected by Western blots (see Example 5), or for secretion ofphosphatase activity.

However when the construct was transfected into a bacterial strainBL21DE3 [52] which is deficient in proteases, a band of the correct size(as well as degraded products) was detected on the Western blots.Furthermore phosphatase activity could now be detected in the bacterialsupernatant. Such activity is not present in supernatant from the strainwhich had not been transfected with the construct.

A variety of linker sequences could then be introduced at the BstEIIsite to improve the spacing between the two domains.

EXAMPLE 11

Coexpression of VH domains with Vk repertoire

A repertoire of Vκ genes was derived by PCR using primers as describedin Example 2 from DNA prepared from mouse spleen and also from mousespleen mRNA using the primers VK3FOR and VK2BACK and a cycle of 94° C.for 1 min, 60° C. for 1 min, 72° C. for 2 min. The PCR amplified DNA wasfractionated on the agarose gel, the band excised and cloned into avector which carries the VHLYS domain (from the D1.3 antibody), and acloning site (SacI and XhoI) for cloning of the light chain variabledomains with a myc tail (pSW1VHLYS-VKPOLYMYC, FIG. 22).

Clones were screened for lysozyme binding activities as described inExamples 5 and 7 via the myc tag on the light chain variable domain, asthis should permit the following kinds of Vκ domains to be identified:

(1) those which bind to lysozyme in the absence of the VHLYS domain;

(2) those which associate with the heavy chain and make no contributionto binding of lysozyme; and

(3) those which associate with the heavy chain and also contribute tobinding of lysozyme (either helping or hindering).

This would not identify those Vκ domains which associated with the VHLYSdomain and completely abolished its binding to lysozyme.

In a further experiment, the VHLYS domain was replaced by the heavychain variable domain VH3 which had been isolated from the repertoire(see Example 6), and then the Vκ domains cloned into the vector. (rotethat the VH3 domain has an internal SacI site and this was first removedto allow the cloning of the Vκ repertoire as SacI-XhoI fragments.)

By screening the supernatant using the ELISA described in Example 6,bacterial supernatants will be identified which bind lysozyme.

EXAMPLE 12

High expression of VH domains.

By screening several clones from a VH library derived from a mouseimmunised with lysozyme via a Western blot, using the 9E10 antibodydirected against the peptide tag, one clone was noted with very highlevels of expression of the domain (estimated as 25-50 mg/l). The clonewas sequenced to determine the nature of the sequence. The sequenceproved to be closely related to that of the VHLYS domain, except with afew amino acid changes (FIG. 23). The result was unexpected, and showsthat a limited number of amino acid changes, perhaps even a single aminoacid substitution, can cause greatly elevated levels of expression.

By making mutations of the high expressing domain at these residues, itwas found that a single amino acid change in the VHLYS domain (Asn 35 toHis) is sufficient to cause the domain to be expressed at high levels.

CONCLUSION

It can thus be seen that the present invention enables the cloning,amplification and expression of heavy and light chain variable domainencoding sequences in a much more simple manner than was previouslypossible. It also shows that isolated variable domains or such domainslinked to effector molecules are unexpectedly useful.

It will be appreciated that the present invention has been describedabove by way of example only and that variations and modifications maybe made by the skilled person without departing from the scope of theinvention.

List of References

[1] Inbar et al., PNAS-USA, 69, 2659-2662, 1972.

[2] Amit et al., Science, 233, 747, 1986.

[3] Satow et al., J. Mol. Biol., 190, 593, 1986.

[4] Colman et al., Nature, 326, 358, 1987.

[5] Sheriff et al., PNAS-USA, 84, 8075-8079, 1987.

[6] Padlan et al., PNAS-USA, 86, 5938-5942, 1989.

[7] Skerra and Plückthun, Science, 240, 1038-1041, 1988.

[8] Bird et al., Science, 242, 423-426, 1988.

[9] Huston et al., PNAS-USA, 85, 5879-5833, 1988.

[10] Fleischman, Arch. Biochem. Biophys. Suppl., 1, 174, 1966.

[11] Porter and Weir, J. Cell. Physiol. Suppl., 1, 51, 1967.

[12] Jaton et al., Biochemistry, 7, 4185, 1968.

[13] Rockey, J. Exp. Med., 125, 249, 1967.

[14] Stevenson, Biochem. J., 133, 827-836, 1973.

[15] Edmundson et al., Biochemistry, 14, 3953, 1975.

[16] Rossman et al., Nature, 317, 145-153, 1985.

[17] Saiki et al., Science, 230, 1350-1354, 1985.

[18] Larrick et al., Biochem. Biophys. Res. Comm., 160, 1250, 1989.

[19] Orlandi et al., PNAS-USA, 86, 3833, 1989.

[20] Yon and Fried, Nuc. Acids Res., 17, 4895, 1989

[21] Fields and Song, Nature, 340, 245-246, 1989.

[22] Baldwin and Schultz, Science, 245, 1104-1107, 1989.

[23] Menard et al., Cancer Res., 43, 1295-1300, 1983.

[24] Bosslet et al., Eur. J. Nuc. Med., 14, 523-528, 1988.

[25] Bosslet et al., Cancer Immunol. Immunother., 23, 185-191, 1986.

[26] Bosslet et al., Int. J. Cancer, 36, 75-84, 1985.

[27]

[28] Bremer et al., J. Biol. Chem., 259, 14773-14777, 1984.

[29] Griffiths & Milstein, Hybridoma Technology in the Biosciences andMedicine, 103-115, 1985.

[30] Maniatis et al., Molecular Cloning: a Laboratory Manual, ColdSpring Harbour Laboratory, 1982.

[31] Jones et al., Nature, 321, 522-525, 1986.

[32] Zoller & Smith, Nuc. Acids Res., 10, 6457-6500, 1982.

[33] Carter et al., Nuc. Acids Res., 13, 4431-4443, 1985.

[34] Sanger et al., PNAS-USA, 74, 5463-5467, 1977.

[35] Yannisch-Perron et al., Gene, 33, 103-119, 1985.

[36]

[37] Riechmann et al., Nature, 332, 323-327, 1988.

[38] Kearney et al., J. Immunol., 123, 1548-1550, 1979.

[39] Potter et al., PNAS-USA, 81, 7161-7163, 1984.

[40] Galfre & Milstein, Meth. Enzym., 73, 1-46, 1981.

[41] Laemmli, Nature, 227, 680-685, 1970.

[42] Better et al., Science, 240, 1041, 1988.

[43] Lei et al., J. Bacteriol., 169, 4379, 1987.

[44] Verhoeyen et al., Science, 239, 1534, 1988.

[45] Gronenborn, Mol. Gen. Genet, 148, 243, 1976.

[46] Dagert et al., Gene, 6, 23, 1974.

[47] Hanahan, J. Mol. Biol., 166, 557, 1983.

[48] Jones et al., Nature, 321, 522, 1986.

[49] Segal, Enzyme Kinetics, 73, Wiley, New York, 1975.

[50] Gutfreund, Enzymes, Physical Principles, Wiley Interscience,London, 1972.

[51] Chaidaroglou, Biochem., 27, 8338, 1988.

[52] Grodberg and Dunn, J. Bacteriol., 170, 1245-1253, 1988.

What is claimed is:
 1. A library for expression of immunoglobulin heavychain variable domains (VH domains), said library comprising arepertoire of nucleic acid sequences encoding a third CDR of animmunoglobulin heavy chain variable domain, each member of saidrepertoire being flanked by VH sequences so as to provide nucleic acidencoding a repertoire of immunoglobulin heavy chain variable domainswhich are identical except for said third CDR.
 2. A library according toclaim 1 wherein said third CDRs are derived from preexisting repertoiresof CDRs.
 3. A library according to claim 1 wherein said third CDRscomprise random sequences.
 4. A library according to claim 1 whereinsaid nucleic acid encoding a repertoire of immunoglobulin heavy chainvariable domains further comprises a sequence encoding one or moreconstant domains for expression of Ig-type chains.
 5. A method forgenerating an antibody variable domain expression library having adiversity of CDR3 sequences, said method comprising: providingexpression vectors, said vectors comprising a variable domain encodingsequence of an antibody; introducing by mutagenesis a diversity of CDR3sequences into said variable domain encoding sequence; and recovering anexpression library having a diversity of binding activities.
 6. Themethod of claim 5 wherein said antibody variable domain is a VH domain.7. The method of claim 5 wherein said expression vector encodes an Fabantibody fragment.
 8. The method of claim 5 wherein said expressionvector encodes a scFv fragment.
 9. An expression library which expressesantibody variable domains, said library comprising a universal set offramework regions carrying a diversity of CDR3 sequences, said libraryhaving a diversity of binding activities.
 10. The expression library ofclaim 9 wherein said antibody variable domains are VH domains.
 11. Theexpression library of claim 9 wherein said antibody variable domains areVL domains.
 12. The expression library of claim 9 wherein said variabledomains are expressed in the form of Fab antibody fragments.
 13. Anexpression library which expresses antibody variable domains having CDRdiversity in only the CDR3 sequences, said library having a diversity ofbinding activities.
 14. The expression library of claim 13 wherein saidantibody variable domains are VH domains.
 15. The expression library ofclaim 13 wherein said antibody variable domains are VL domains.
 16. Theexpression library of claim 13 wherein said variable domains areexpressed in the form of Fab antibody fragments.
 17. The expressionlibrary of claim 13 wherein said variable domains are expressed in theform of scFv antibody fragments.
 18. An expression library produced bythe method of claim
 5. 19. An expression library produced by the methodof claim
 6. 20. An expression library produced by the method of claim 7.21. An expression library produced by the method of claim 8.